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Over the past century, catalysis has become an essential tool for chemical and material 
manufacturing and pollution control systems. In particular, the potential of this technology to 
efficiently produce specialty and fine chemicals, including many pharmaceuticals is proven.[1] 
The huge impact of catalysis on society was well recognized by the Nobel Foundation (Table 
1).[2] 
Table 1: Contributions in catalysis recognized by the Nobel Foundation 
 
Awardees (year) Research contribution 
W. Ostwald (1909) Catalysis, chemical equilibria, and reaction rates 
P. Sabatier (1912) Hydrogenation of organic compounds in presence 
of finely divided metals 
F. Haber (1918) Synthesis of ammonia from its elements 
K. Ziegler and G. Natta (1963) Discoveries in the field of chemistry and 
technology of high polymers 
W. S. Knowles, R. Noyori, and K. Barry 
Sharpless (2001) 
Chirally catalyzed hydrogenation and oxidation 
Y. Chauvin, R. H. Grubbs, and 
R.R. Schrock (2005) 
Development of metathesis method 
G. Ertl (2007) Studies of chemical processes on solid surfaces 
R. F. Heck, E. Negishi and A. Suzuki 
(2010) 
Palladium-catalyzed cross-coupling methods 
 
1.2 Transition metal catalyzed C−H bond functionalization 
Transition-metal-catalyzed reactions are vital to modern organic synthesis because the 
distinctive reactivity of transition metals allows highly selective and efficient transformations 
that are not possible with conventional methods. Synthesis of complex molecules using C–H 
bond functionalization[3] has become an essential tool in synthetic chemist's toolbox as it 





approach provides a perfect opportunity for late stage diversification and is driven by 
environmental and economic requirements. 
 
 
Scheme 1: Comparision of C–H activation vs conventional functional group interconversion 
 
Owing to the presence of multiple C–H bonds in all kinds of organic molecules, achieving 
efficient, selective and predictable transformations is a challenging task. As organic 
molecules contain C–H bonds with comparable bond dissociation energies, the use of a 
Lewis basic directing group that coordinates to the transition metal is essential to achieve 
selectivity.[4] A directing group enables intramolecular cleavage of the C–H bond leading to a 
regioselective functionalization (Scheme 2). 
 
 
Scheme 2: Directing group(DG) strategy for intermolecular cleavage of C–H bond 
 
1.3 Prices of transition metal catalysts 
Efficient, selective, and direct functionalization of C−H bonds with less expensive transition 
metals under mild conditions remains the most difficult challenge. The prices of gold, 
platinum, rhodium, palladium, iridium, and ruthenium were 1326, 1049, 675, 665, 650, 42 
US$ per troy oz, respectively.[5] The demand for more abundant and less expensive 






1.4 Mechanisms of C−H bond functionalization 
Depending on the nature of the transition metal M and ligand set Ln, the elementary step of 
C−H bond metalation was proposed to proceed via different pathways.[7] The four important 
classes, involving the formation of stable organometallic species are: a) Oxidative addition 
(OA) - characteristic for electron rich and low valent late transition metals; b) σ-bond 
metathesis (SBM) - characteristic for late transition metals with d0 configuration; 
c) electrophilic activation (EA) - typical for late or a post-transition metal usually in strong 




Scheme 3: Possible mechanisms for C–H bond metalation by transition metal complexes 
 
1.5 General approach for the synthesis of biaryls 
Regioselective syntheses of bi(hetero)aryls are mainly achieved by the use of highly efficient 
transition-metal-catalyzed cross-coupling reactions between organic (pseudo)halides and 
stoichiometric amounts of organometallic reagents.[8] A major drawback of these 
cross-coupling reactions is that the organometallic nucleophilic reagents are often not 
commercially available, relatively expensive and involve preparation from the corresponding 
arenes, during which undesired by-products are formed. Therefore, direct arylation reactions 
by direct cleavage of C–H bonds are more efficient regarding both atom- and step-economy. 
Tremendous savings in solvent, waste and energy enable the use of this strategy for the 





Approaches for biaryl synthesis are based on the nature of coupling partners: a) cross 
dehydrogenative coupling, b) cross coupling reactions and c) reactions with aryl (pseudo) 
halides (Scheme 4). 
a) Cross-Dehydrogenative Coupling (CDC): Very challenging and highly desirable is the 
selective formation of carbon–carbon bonds directly from two different C–H bonds via the 
formal removal of two hydrogen atoms.[9] Controlling the chemo-selectivity of cross- versus 
homo dehydrogenative arylations and positional selectivity in intermolecular direct arylations 
are major limitations. Use of a stoichiometric oxidant and use of super stoichiometric arene 
also reduces the atom-economy of CDC coupling.  
b) Cross coupling reactions make use of regioselective coupling between organometallic 
reagents as nucleophiles and aryl (pseudo)halides as electrophile. Generally, synthesis of 
organometallic reagents from corresponding aryl halides is tedious and expensive. 
Moreover, stoichiometric terminal oxidants like copper(II) or silver(I) salts are employed in 
the arylation step. Although this process is highly reliable, atom-economy and step-economy 
are still limitations for a sustainable approach. 
c) Reactions in which unfunctionalized (hetero)arenes are directly employed as the starting 
materials and functionalized through C–H bond cleavages. Direct arylations with relatively 
inexpensive organic (pseudo)halides as the arylating reagents is definitely a more attractive 










1.6 Ruthenium catalyzed direct arylations of C(sp2)–H bonds 
The ruthenium-catalyzed direct arylation of C(sp2)–H bonds using chelation assistance from 
pyridines was developed by Inoue and co-workers (Scheme 5).[11] Aryl bromides or aryl 
iodides were used as arylating agents. Subsequently, Inoue used the same reaction 
conditions for various other directing groups like imine[12] and oxazoline.[13] After few years, it 
was found researchers at Merck that these results could not be reproduced.[14] Aryl chlorides 
were ineffective under these reaction conditions. 
 
 
Scheme 5: Ruthenium-catalyzed direct arylation by Inoue using phosphine ligands 
 
However, a major breakthrough in ruthenium-catalyzed direct arylations was achieved by 
Ackermann in 2005 (Scheme 5) overcoming the limitations of conditions developed by 
Inoue.[15] Reactions with aryl chlorides or tosylates proceeded with excellent chemo- and 
site-selectivity when phosphine oxides are used as ligands.[16] This approach is more 








Scheme 6: Ruthenium-catalyzed direct arylation with phosphine oxide ligands 
 
This catalytic system was further improved using carboxylic acids as co-catalysts instead of 
phosphine oxides (Scheme 7).[17] A variety of directing groups could be used to achieve 
C(sp2)–H bond arylation using aryl(pseudo) halides with the highly robust catalytic system. 
 
 






Detailed mechanistic studies indicated that ruthenium carboxylate complexes are the actual 
catalysts in the reaction.[18] Using cheaper and more abundant carboxylic acids as co-
catalysts will provide a chance to enhance the reactivity profile and robustness. The 
remarkable robustness of ruthenium carboxylate complexes was also proven ro be 
applicable for alkylations using primary, secondary and tertiary alkyl halides.[19]  
 
1.7 Angiotensin II receptor blockers 
Taking the advantages of direct arylation via C–H bond functionalization over cross-coupling 
chemistry methods into account, it would be very economical to apply this method to 
synthesize molecules of pharmaceutical interest. Angiotensin II receptor blockers (ARBs),[20] 
containing a biaryl tetrazole unit are identified as target molecules to apply ruthenium-
catalyzed direct arylation methods (Figure 1). 
 
 






More than 1000 tons ARBs are produced per annum. Losartan (10) and Valsartan (8) are 
top selling drugs in this category. Previous synthetic methods suffer from several drawbacks 




Figure 2: Cross-coupling with boron reagent vs direct arylation with aryl(pseudo)halide  
 
The standard method to synthesize the biaryl unit in sartan drugs employs Suzuki-Miyaura 
coupling with boronic acid derivative 14 as the starting material and the reaction occurs with 
overall low efficency.[22] Therefore, there is an urgent need to develop a more sustainable 
method for the synthesis of ARBs using C–H bond arylation strategy. While efforts to 
synthesize biaryltetrazoles using carboxylate-assisted ruthenium catalyzed arylation were in 
progress in our group, Seki published a ruthenium-catalyzed direct arylation protocol to 
synthesize Valsartan with phosphine ligands developed by Oi and Inoue.[23] Later this 
reaction was found to be inefficient for pilot scale production of biaryl tetrazole. Similar 
results were observed by the process research division of Merck in the pilot scale synthesis 
of Anacetrapib when the Oi and Inoue phopshine-based ruthenium catalytic system failed to 





present in NMP is the cause for irreproducibility and therefore a more robust catalytic system 
is needed. Exploring ruthenium(II) carboxylate complexes such as [Ru(O2CMes)2(p-
cymene)] (16) might be beneficial as they were already proven to be efficient in direct 
arylations.[25] 
 
1.8 Ruthenium catalyzed direct arylations of C(sp3)–H bonds 
Catalytic functionalization of C(sp3)–H bonds in a selective fashion is very challenging due to 
the lack of π-orbitals that can interact with transition metals. As a result TM-catalyzed 
functionalization of C(sp3)–H bonds are not very successful compared to functionalization of 
C(sp2)–H bonds.[26] Considering the prevalence of functionalized saturated cyclic amines in 
molecules of pharmaceutical interest (Figure 3), it is very crucial to develop methods for the 
functionalization of cyclic amines to overcome the limitations of existing methods that involve 
the usage of stoichiometric lithiated reagents and cryogenic conditions.[27]  
 
 
Figure 3: Representative examples of biologically active substituted cyclic amines  
 
Molecules containing diarylmethylamine are also an important class of pharmaceutically 
active compounds (Figure 4).[28] They have a variety of biological activities such as 
antihistamanics[29] (e.g., Cetirizine) and antidepressants (e.g., Tianeptine).[30] Various 







Figure 4: Representative examples of drugs containing diarylmethyl amine unit  
 
Ruthenium catalyzed C(sp3)–H bond arylations are scarce in the literature (Scheme 8). 
Sames achieved chelation assisted α-arylation of pyrrolidines using removable (amidine) 
directing group.[31] Using similar reaction conditions as of Sames, and pyridine as the 
directing group, Maes developed a protocol for α-arylation of piperidines.[32] Schnurch also 
reported C(sp3)–H bond arylations in benzylic amines using pyridine as the directing 
group.[33] However, the use of rather expensive Ru(0) catalysts and aryl boronates as 






Scheme 8: Ruthenium-catalyzed arylation of C(sp3)–H bonds using aryl boron reagents 
 
Carboxylate assistance proved to overcome the drawbacks of this method (Scheme 9). 
However, pre-stirring of the catalyst with substoichiometric amount of co-catalyst is a 
limitation of this method.[34] 
 






1.9 Ruthenium-Catalyzed Hydroarylation of Alkynes 
Alkyl and vinyl arenes are produced on a large scale every year as they are useful 
intermediates for fine chemical synthesis and are key structural motifs in various important 
compounds in natural products,[35] in material sciences[36] and medicinal chemistry.[37] The 
addition of aromatic C–H bonds across alkene and across alkyne is an important synthetic 
method as it is the most efficient way to form a new C–C bond. A pioneering example of 
ruthenium-catalyzed addition of aromatic C–H bond in ketones (30) to internal alkynes was 
reported by Murai and coworkers in 1995 (Scheme 10).[38] The reaction occured with high 
site-selectively and regio-selectivity when trimethylsilyl substituted acetylenes were 




Scheme 10: Hydroarylation of internal alkynes using ketone as the DG 
 
Much progress was not made for hydroarylation of alkynes using ruthenium catalysis until 
recently. Miura and coworkers reported amide directed regio- and stereo-selective 
hydroarylation in 2012 (Scheme 11).[39] Subsequently, Miura showed the efficiency of this 
catalytic system with various directing groups, such as imidazole, pyrazole, phosphine 







Scheme 11: Hydroarylation of alkynes by Miura 
 
Jeganmohan could employ aryl carbamates, acetanilides and aromatic sulfoxides by a slight 
variation in the Miura's catalytic system (Scheme 12).[41]  
 
 
Scheme 12: Hydroarylation of alkynes with various directing groups by Jeganmohan 
 
Pyridine was used as a removable directing group(rDG)[42] to achieve C2-functionalization of 






Scheme 13: C2-functionalization of Indole using removable directing group. 
 
Hydroarylation of alkynes could be achieved employing triazole as directing group by Liu and 
Ackermann's group achieved the oxidative alkenylation with activated alkenes 
(Scheme 14).[44]  
 
 
Scheme 14: Triazole-directed hydroarylation of alkynes. 
 
Benzylthioethers were also used as substrates for hydroarylation of internal alkynes under 
microwave conditions.[45] Very recently, Ackermann and co-workers achieved aerobic 
oxidative C–H functionalization of weakly coordinating benzoic acids with oxygen or ambient 
air (Scheme 15). The alkenylation protocol with activated alkenes afforded phthalides[46] in a 
step-economic fashion.[47] Furthermore, the aerobic alkyne annulation method allowed the 
synthesis of isocoumarins.[48] Most importantly, use of oxygen as cheapest sacrificial oxidant 








Scheme 15: Ruthenium catalyzed annulations with O2 as oxidant  
 
1.10 Transition metal catalyzed C–B bond formation 
Boronic acids or their more stable derivatives, such as boronic esters and trifluoroborate 
salts are versatile compounds in organic synthesis as they can act as transient functional 
groups and intermediates in cross coupling technology,[50] enzyme inhibitors,[51] and boron 
neutron capture therapy agents.[52]  
 
 
Figure 5: Boron-containing anti-cancer agents  
 
While Velcade® and Ninlaro® are approved drugs (Figure 5), there are many other boron 
containing compounds showing promising activity as enzyme inhibitors. In particular, the 
enormous potential of compounds containing α-amino boronic acid in their structure has 







Figure 6: Pharmacologically relevant boron containing inhibitors 
 
Traditional methods to synthesize boronic acids include: a) halogen-boron exchange with 
aryl halides and b) directed ortho-metallation along with subsequent borylation 
(Scheme 16).[54] The traditional methods are limited by functional group incompatibility, 
stoichiometric organometallic reagents, and the requirement of strict anhydrous and 
cryogenic conditions. 
 
Scheme 16: Traditional approaches for the preparation of boronic acids 
 
The first catalytic approach for the preparation of organo boronates was developed by 





catalyzed cross-coupling reaction between B2pin2 and aryl (pseudo)-halides (Suzuki-Miyaura 
borylation) offered a more reliable approach for the synthesis of aryl/alkyl boronates. The 
use of preactivated substrates is a limitation in the Suzuki-Miyaura borylation. A more atom-
economic approach by direct C–H bond functionalization is highly desirable. 
 
 
Scheme 17: Suzukui-Miyaura borylation 
 
Early contributions from Hartwig, Smith, Miyaura and Marder include efficient procedures for 
arene and alkane borylation using expensive rhodium and iridium catalysts (Scheme 18).[56] 
Site-selectivity was mainly controlled by steric interactions in case of arene borylation, thus 
obviating the use of a directing group. 
 
 
Scheme 18: Transition metal catalyzed C–H borylation 
 
Considerable progress has been made in the last few years using a strategy involving 
directing group by Sawamura, Yu, Fernandez and others (Scheme 19).[57] 
 
 






1.11 Ruthenium-catalyzed C–H borylation 
In 2006, Hartwig and co-workers reported the first ruthenium-catalyzed C–H borylation 
(Scheme 20). Regiospecific terminal borylation of alkanes was achieved using [Cp*RuCl2]2 at 
high temperatures under neat conditions.[58] Notably, preferential borylation was observed at 
the less hindered methyl group even when heteroatoms were present. The sensitive nature 
of the catalyst and the use of overstoichiometric reagent limit the practical applicability. 
 
 
Scheme 20: Site-selective alkane borylation 
 
Mullen and coworkers reported the ruthenium-catalyzed C(sp2)–H borylation in 2011 
(Scheme 21). The authors successfully achieved chelation-assisted tetraborylation in 
Perylenediimide (PDI) using [RuH2(CO)(PPh3)3].[59] Furthermore, boron derivatives of PDI 







Scheme 21: Tetraborylation of PDI 
 
Nolan et al. achieved ruthenium catalyzed ortho-selective C–H borylation of 2-phenyl 
pyridine derivatives using B2pin2 62a as the borylating agent (Scheme 22).[60] The authors 
employed 3-phenylindenyldihydridosilyl ruthenium complexes. However, the high cost of the 
precursor complex [RuCl(PPh3)2(3-phenylindenyl)] and the sensitive nature of the catalyst 
are major limitations of this method.[61] 
 
 
Scheme 22: Pyridine-directed borylation using B2pin2 
 
Murata employed [RuH2(CO)(PPh3)3] to achieve ortho-selective C–H borylation of 2-phenyl 
















Ruthenium(II) complexes have emerged as effective catalysts for C−H arylations of arenes 
by chelation assistance with organic halides or pseudohalides, which allowed for the step-
economical synthesis of biaryl compounds. Ackermann's group reported the use of 
bifunctional additives, such as carboxylates and phosphates, as co-catalysts for ruthenium-
catalyzed direct arylations in apolar solvents via a concerted metalation-deprotonation 
(CMD) mechanism.[63] Carboxylates are the first choice of additives in transition-metal 
catalyzed C–H bond fucntionalization due to their easy availability, low cost and stability. 
Continuing these efforts to apply carboxylate-assisted ruthenium-catalyzed direct arylation 
using tetrazoles as directing group is of critical importance as this potentially forms the key 
step in the syntheses of various block buster drugs, such as Losartan, Valsartan and 
Candesartan Cilexetil (Scheme 24). 
 
 
Scheme 24: Ruthenium-catalyzed C(sp2)–H arylation  
 
Transition metal-catalyzed functionalizations of C(sp3)–H bonds are not very successful 
compared to direct C(sp2)–H bond functionalizations due to the challenges involved in the 
catalytic functionalisation of C(sp3)–H bonds. Developing user-friendly single component 
catalysts for C(sp3)–H bond functionalization is a great challenge. Towards this goal probing 
various ruthenium(II) carboxylate complexes to achieve direct C(sp3)–H bond 
functionalization might be advantageous. This project overcomes the challenges involved in 
direct arylations of C(sp3)–H bonds using carboxylate-assisted ruthenium catalysis and its 
application to synthesize molecules containing the diarylmethylamine unit, an important 







Scheme 25: Ruthenium-catalyzed C(sp3)–H arylation  
 
Ackermann and coworkers have disclosed ruthenium-catalyzed oxidative annulations of 
benzoic acids with activated alkenes and internal alkynes using oxygen as the terminal 
oxidant.[64] Benzoic acids are versatile starting materials for C–H bond fucntionalization due 
to their low cost and abundance.[65] Development of reactions using carboxylic acids as 
removable directing groups is very important as it provides a strategy to access meta-
substituted arenes in a higly selective fashion obviating the use of templates.[66] We were 
interested in using readily available carboxylic acids as removable directing groups for 
hydroarylation reaction. More importantly, various meta-substituted arenes of high synthetic 
value should be prepared using this methodology (Scheme 26). 
 
 
Scheme 26: Ruthenium-catalyzed C(sp2)–H hydroarylation 
 
The borylation of C–H bonds has received considerable attention in recent years because of 
the transformative nature of boronic acid derivatives as inter alia transient functional groups 
in cross-couplings technology and beyond. Site-selective borylations directed by sterics or 
directing groups are typically achieved using rather expensive iridium, rhodium, and 
palladium complexes.[67] Despite the power of organoboron compounds in organic synthesis, 





development of highly robust and inexpensive ruthenium(II) complexes as pre-catalysts for 
C–H borylation still remains a challenge in this field (Scheme 27). 
 
 
Scheme 27: Ruthenium-catalyzed borylation of C(sp3)–H and C(sp2)–H bonds 
 




Results and discussion 
3.1 Ruthenium-catalyzed C–H arylation of phenyltetrazoles 
3.1.1 Scope of phenyltetrazoles in ruthenium-catalyzed direct arylation 
Under optimized conditions by E.Diers,[68] the scope of the ruthenium-catalyzed arylation 
with tetrazoles as the directing group was explored. Initially, the scope of the reaction with 
respect to the electrophiles employed under the optimized reaction conditions was explored 
using meta-substituted derivatives 2 (Scheme 28). Aryl iodide 78, aryl bromide 2b and aryl 
triflate 80a proved to be effective with similar reactivity. Unfortunately, more economical aryl 
chlorides 79 showed inferior reactivity. 
 
 
Scheme 28: Scope of tetrazole-directed C–H arylations with various aryl (pseudo)halides 
 
Differently N-substituted tetrazoles were tested and a similar reactivity was observed with N-
PMB substituted tetrazole 15b compared to simple N-benzyl substitued tetrazole 15a. 
Further scope was investigated with N-benzyl functional group on tetrazole 15a as it is more 
atom economic and easily cleavable (Scheme 29). 





Scheme 29: Effect of the N-substituent on the tetrazole directing group 
 
The versatility of the reaction was studied with electronically different aryl bromides 2 
(Scheme 30). Aryl bromide 2c with an enolizable ketone delivered the desired product 71ac. 
The efficiency of the reaction was higher with electron-rich substrate 2e than with electron 
deficient 2f. Hetero-aryl bromides were also tested as electrophilic substrates. The reactivity 
profile was similar to that of aryl bromides, as the electron-rich electrophile 2h was more 
reactive than 2g.  





Scheme 30: Scope of tetrazole-directed arylations with aryl bromides 
 
3.1.2 Arylation of phenyltetrazole with well-defined ruthenium(II) complex 
To gain insight into the catalyst's mode of action, the well defined ruthenium(II) 
biscarboxylate complex (16) was employed as the catalyst. The catalyst 16 showed 
comparable reactivity and selectivity with the in situ formed catalytic system (Scheme 31). 
More importantly, the yield of the reaction showed only a slight decrease when the 
ruthenium loading was reduced to 5 mol % and delivered exclusively the monoarylated 
product 71ac. 
 





Scheme 31: C–H arylation with ruthenium(II) biscarboxylate complex 
 
3.1.3 Proposed mechanism for C–H arylation of phenyltetrazole 
Based on the mechanistic studies in our group,[69] the following mechanism is proposed. An 
initial reversible cyclometalation is plausible through chelation assistance from tetrazole to 
give complex B (Scheme 32) and subsequently formal oxidative addition of aryl(pseudo) 
halide 2 by a SET-type process give complex C. Reductive elimination from C delivers 
product 71.  
 
 
Scheme 32: Plausible mechanistic cycle for arylation of phenyltetrazole 15. [Ru] = [Ru(O2CMes)(p-
cymene)




3.2 Ruthenium-catalyzed C(sp3)–H arylation 
3.2.1 Optimization studies for ruthenium-catalyzed C(sp3)–H arylation 
A variety of reaction conditions were tested for the envisioned ruthenium-catalyzed C(sp3)–H 
arylation of benzyl amine 27a with bromo benzene (2i) (Table 2). 
Table 2. Optimization of C(sp3)–H arylation 
 
Entry Cat [Ru] Additive Base Yield (%)[a] 
1 [Ru(O2CMes)2(p-cymene)] -- K2CO3 60 
2 [Ru(O2CMes)2(p-cymene)] -- NaOAc 13 
3 [Ru(O2CMes)2(p-cymene)] -- KOAc 17 
4 [Ru(O2CMes)2(p-cymene)] -- K3PO4 46 
5 [Ru(O2CMes)2(p-cymene)] -- K2CO3 51[b] 
6 [Ru(O2CMes)2(p-cymene)] -- Na2CO3 69 
7 [Ru(O2CMes)2(p-cymene)] (1-Ad)2P(O)H Na2CO3 40 
8 [Ru(O2CMes)2(p-cymene)] 1-AdCO2H Na2CO3 55 
9 [Ru(O2CMes)2(p-cymene)] MesCO2K K2CO3 55 
10 [Ru(O2CMes)2(p-cymene)] -- K2CO3 --[c] 
11 [Ru(O2CMes)2(p-cymene)] -- K2CO3 --[d] 
12 [Ru(O2CMes)2(p-cymene)] -- K2CO3 40[e] 
13 [Ru(OPiv)2(p-cymene)] -- K2CO3 51 
14 [Ru(OPiv)2(p-cymene)] KOPiv K2CO3 58 
15 [RuCl2(p-cymene)]2 -- Na2CO3 39 
16 [RuCl2(p-cymene)]2 MesCO2K K2CO3 50 
17 [RuCl2(p-cymene)]2 MesCO2H K2CO3 41 




Entry Cat [Ru] Additive Base Yield (%)[a] 
18 [RuCl2(p-cymene)]2 (1-Ad)2P(O)H K2CO3 36 
19 [RuCl2(p-cymene)]2 (t-Bu)2P(O)H K2CO3 42 
20 [RuCl2(p-cymene)]2 PCy3 K2CO3 -- 
21 [RuCl2(p-cymene)]2 KOAc K2CO3 47 
22 [RuCl2(p-cymene)]2 -- K2CO3 36 
23 [RuCl2(p-cymene)]2 -- KOAc 58 
24 [RuCl2(p-cymene)]2 (1-Ad)2P(O)H Na2CO3 55 
25 [RuBr2(p-cymene)]2 -- Na2CO3 51 
26 [RuBr2(p-cymene)]2 -- K2CO3 48 
27 -- -- Na2CO3 - 
[a] Reaction conditions: 27a (0.50 mmol), 2i (0.75 mmol), [Ru] (5.0 mol %), additive (30 mol %), base (1.50 mmol), 
solvent (2.0 mL), 140 °C, 24 h; isolated yields. [b] [Ru] (2.5 mol %). [c] DMF as the solvent. [d] H2O as solvent. 
[e] NMP as solvent. 
 
Among the ruthenium(II) carboxylate complexes probed, [Ru(O2CMes)2(p-cymene)] showed 
superior reactivity as compared to [Ru(OPiv)2(p-cymene)]. The reaction was shut down 
completely when polar solvents such as DMF or H2O, were employed (entries 10 and 11). 
[RuCl2(p-cymene)]2 showed inferior reactivity even in presence of various additives such as 
phosphine oxides or carboxylates (entries 15-26). Among the various stoichiometric bases 
screened, Na2CO3 showed superior reactivity (entry 6) as compared to other bases, 
including K2CO3, KOAc, NaOAc or K3PO4 (entries 1-4). A control experiment (entry 27) 
demonstrated that the reaction did not occur in the absence of a ruthenium catalyst. 
3.2.2 Scope of C(sp3)–H bond Arylation 
After optimizing the reaction conditions, the effect of the substitution pattern of the pyridine 
moiety in substrates 27 was studied (Scheme 33). Pyridine 27b without an additional 
substituent and other substituents (27c-27e) gave unsatisfactory results. Pyridine derivative 
27a bearing a 3-methyl group was found to be the best. 
 





Scheme 33: Variation of pyridine substitution  
 
With regard to the choice of electrophiles employed under the optimized reaction conditions, 
only aryl bromides 2 were efficient. Other electrophiles did not afford the desired product 
29ai (Scheme 34). 
 
 
Scheme 34: Variation of Aryl(pseudo) halides 2 
 
With the optimized reaction conditions in hand, the scope of the reaction was studied with 
various (hetero)aryl bromides 2 as the electrophiles. The broad scope and remarkable 
functional group tolerance were exemplified by the synthetically useful chloride substituent, 
which should prove valuable for subsequent derivatization of 29al as well as free (NH)-indole 
29aq (Scheme 35).  





Scheme 35: Scope of C(sp3)–H bond arylation with aryl bromides. [a] At 150 °C 




3.2.3 Limitations of C(sp3)–H bond arylation 
3.2.3.1 Unreactive ortho-aryl bromides 
Reactions with para-substituted aryl bromides 2 and meta-substituted aryl bromides showed 
similar reactivity and good yields were obtained. However, when ortho-substituted aryl 
bromides 2r-t were employed, no formation of products 29 was observed (Figure 7). 
 
 
Figure 7: Unsuccessful ortho substituted aryl bromides 
 
3.2.3.2 Unreactive amines 
Various other substrates containing C(sp3)–H bond and a Lewis basic directing group were 
tested under the optimized reaction conditions (Figure 8). No conversion was observed for 
substrates (Figure 8). Based on these results, a free NH functionality and benzyl group are 
essential for effective arylations. 
 
 
Figure 8: Unsuccesful amines for C(sp3)–H bond arylation 
 




3.2.4 Mechanistic studies for C(sp3)–H arylation 
3.2.4.1 Radical scavenger experiments for C(sp3)–H arylation 
Experiments performed with TEMPO as a radical scavenger in catalytic amounts revealed 
that the reaction efficiency was reduced. Increasing the amount of TEMPO to 
superstoichiometric quantities led to no product (Scheme 36). This indicates that a single-
electron transfer (SET) step might be involved in the catalytic cycle. 
 
 
Scheme 36: Radical scavenger experiments with TEMPO as additives 
 
3.2.4.2 H/D exchange  
H/D exchange studies carried out in the presence of D2O as a co-solvent revealed that a 
significant H/D scrambling occured (Scheme 37). These studies are in favor of a reversible 
C(sp3)–H bond cleavage. 
 
 
Scheme 37: H/D exchange in the presence of D2O 




3.2.4.3 Proposed mechanism for C(sp3)–H arylation 
Competition experiments performed by R. Jeyachandran revealed the importance of a Lewis 
basic directing group and also support a reversible C(sp3)–H cleavage. Based on our 
mechanistic studies, the following mechanism is proposed. An initial reversible 
cyclometalation through pyridine assistance gives complex P (Scheme 37a) and 
subsequently carboxylate assisted C–H ruthenation via transition state Q delivers complex 
R. Formal oxidative addition of arylbromide 2 by a SET-type process furnishes complex S. 
Finally, complex S undergoes reductive elimination to deliver the desired product 29 and 
regenerates the active catalyst 16.  
 
 
Scheme 37a: Plausible mechanism for C(sp3)–H arylation 




3.3 Decarboxylative Ruthenium-catalyzed Hydroarylation of Alkynes 
3.3.1 Optimization studies for Decarboxylative Hydroarylation 
At the outset of the studies, a variety of reaction conditions were tested for the envisioned 
hydroarylation reaction of diphenylacetylene 34a with o-anisic acid 48a (Table 3). There was 
no conversion in the absence of a ruthenium catalyst (entry 1). Among the various ruthenium 
catalysts screened, simple [RuCl2(p-cymene)]2 showed no reactivity, while ruthenium(II) 
carboxylate complexes proved to be highly active. [Ru(O2CMes)2(p-cymene)] (16) showed 
similar reactivity as compared to [Ru(OPiv)2(p-cymene)] (entries 4 and 6). We observed a 
significant decrease in the yield of the desired product 72aa when reducing the reaction 
temperature (entry 3). Reducing the catalyst loading by half caused only a slight decrease in 
the yield of product 72aa (entry 5). The reaction was efficient even in polar solvents such as 
water[70] and alcoholic solvents (entries 7, 8 and 13). However, a considerably low reactivity 
was observed when DMA was employed (entry 10). Toluene and 1,2-dichloroethane proved 
to be the best solvents for this transformation (entries 4 and 11). Carboxylate complexes 
from other transition metals, such as cobalt and palladium did not show any reactivity at all 
and the diphenylacetylene 34a was reisolated in more than 95%). Therefore, ruthenium(II)- 
carboxylate complexes are critical for achieving the desired transformation.The optimized 
reaction conditions are very user friendly as only a single component catalyst is employed. 
No additives, such as copper(II) or silver(I) salts, were required and the reaction occured at 
rather low temperatures. Most importantly, readily available and inexpensive benzoic acids 
could be employed as starting materials to prepare meta-alkenylated arenes without the use 
of a template approach. 








Entry [TM] (x mol %) Solvent Yield [%][a] 
1   - PhMe NR[b] 
2 [RuCl2(p-cymene)]2 (5.0 mol %) PhMe NR[b] 
3 [Ru(O2CMes)2(p-cymene)] (10.0 mol %) PhMe 31[c] 
4 [Ru(O2CMes)2(p-cymene)] (10.0 mol %) PhMe 95 
5 [Ru(O2CMes)2(p-cymene)] (5.0 mol %) PhMe 87 
6 [Ru(OPiv)2(p-cymene)] (10.0 mol %) PhMe 93 
7 [Ru(O2CMes)2(p-cymene)] (10.0 mol %) MeOH 50 
8 [Ru(O2CMes)2(p-cymene)] (10.0 mol %) H2O 71 
9 [Ru(O2CMes)2(p-cymene)] (10.0 mol %) 1,4-dioxane 50 
10 [Ru(O2CMes)2(p-cymene)] (10.0 mol %) DMA 10 
11 [Ru(O2CMes)2(p-cymene)] (10.0 mol %) DCE 98 
12 [Ru(O2CMes)2(p-cymene)] (10.0 mol %) tAmOH 56 
13 Co(OAc)2 (10.0 mol %) PhMe NR[d] 
14 Co(OAc)2 (10.0 mol %) MeOH NR[d] 
15 Pd(OAc)2 (10.0 mol %) PhMe NR[d] 
[a] Reaction conditions: 48a (0.50 mmol), 34a (1.00 mmol), [TM] (x mol %), solvent (2.0 mL), 24 h, N2, 100 °C, 
isolated yields. [b] 34a recovered in 99%. [c] at 60 °C. [d] 34a recovered in >95% yield. 




3.3.2 Scope of Decarboxylative Hydroarylation 
With the optimized reaction condition in hand, the versatility of the catalyst was studied using 
various ortho-substituted benzoic acids (Scheme 38). The functional group tolerance of the 
reaction was exemplified by having substituents, such as fluoro, chloro, and nitro, on the 
benzoic acid. Simple benzoic acid without an ortho-substituent also reacted, but with low 




Scheme 38: Decarboxylative Hydroarylation of Alkynes 34. [a] In DCE 
 
The reactivity trend observed in the hydroarylation of alkynes 34 with benzoic acids 48 is 
difficult to explain as factors such as solubulity of the substrates in the reaction medium and 
acidity of the benzoic acid are important, but can not be quantified easily. To verify if the 
efficiency of the reaction is dependent on the ortho-substituent, the scope of the reaction 
was also studied with para-substituted benzoic acids 48a', 48h and 48i (Scheme 39). 
Gratifyingly, the desired products 72 were obtained in good yields. 
 





Scheme 39: Decarboxylative Hydroarylation with para-substituted Benzoic acids. [a] In DCE 
 
To test the robustness of the novel decarboxylative method, more challenging substrates 
namely salicylic acid derivatives were employed. Interestingly, the desired product 72ja was 
obtained in good to excellent yields (Scheme 40). Most importantly, a highly inexpensive and 
bio-renewable phenolic acid was used as a starting material to prepare a meta-anlaogue 




Scheme 40: Decarboxylative Hydroarylation with Salicylic acid 48j 
 
3.3.3 Mechanistic investigations for hydroarylation reaction 
Several experiments were performed to clarify if the hydroarylation the formal loss of CO2 
proceeds in a simultaneous or a consecutive fashion. Hydroarylated products with carboxylic 
acid group intact 72ka' could be isolated (Scheme 41). These results indicate that loss of 
CO2 occurs most likely after the hydroarylation step. 





Scheme 41: Hydroarylation of alkyne 34a with m- bromo benzoic acid 48k 
 
Moreover, an experiment performed with 2-napthoic acid 48m under reaction conditions in 
the absence of alkyne did not show the formation of naphthalene, as judged by 1H NMR 
spectroscopic and mass spectroscopic analysis.  
 
 
Scheme 42: Probing decarboxylation in the absence of an alkyne 
 
3.3.4 Limitations of hydroarylation reactions 
The steric and electronic nature of the carboxylic acids and solubulity play a critical role in 
their reactivity towards the hydroarylation of alkyne 34a. Cycloalkyl carboxylic acids and 
polyaromatic acids did thus far, not show any reactivity (Figure 9). 
 





Figure 9: Thus far unsuccessful substrates 48 
 




3.4 Carboxylate-assisted ruthenium-catalyzed C–H borylation 
3.4.1 Optimization of ruthenium-catalyzed C(sp2)–H borylation 
At the outset of our investigations, a variety of reaction conditions were tested for the 
envisioned borylation reaction of benzo[h]quinoline 1a with bis pinacolato diboron 62a 
(Table 4). No conversion was observed in the absence of a catalyst (entry 1). Inexpensive 
RuCl3·xH2O and [RuCl2(p-cymene)]2 were not effective for the desired transformation (entries 
2 and 3) respectively. Various carboxylates were probed as additives (entries 4-8). Thus, the 
desired product 70aa was observed with NaOAc as the addittive (entry 8). Next, well-defined 
ruthenium(II) carboxylates were explored (entries 10-22) in various solvents. The desired 
reaction was most efficient in 1,4-dioxane (entry 10). 
 




Entry [TM] (x mol %) Additive Solvent Yield [%][a] 
1 - - 1,4-dioxane NR 
2 RuCl3·xH2O - 1,4-dioxane NR 
3 [RuCl2(p-cymene)]2 - 1,4-dioxane NR 
4 [RuCl2(p-cymene)]2 AgOAc 1,4-dioxane NR 
5 [RuCl2(p-cymene)]2 CsOAc 1,4-dioxane NR 
6 [RuCl2(p-cymene)]2 KOAc 1,4-dioxane <5 
7 [RuCl2(p-cymene)]2 KOPiv 1,4-dioxane NR 
8 [RuCl2(p-cymene)]2 NaOAc 1,4-dioxane 40 
9 [RuCl2(p-cymene)]2 NaOTs 1,4-dioxane NR 




Entry [TM] (x mol %) Additive Solvent Yield [%][a] 
10 [Ru(O2CMes)2(p-cymene)] - 1,4-dioxane 86 
11 [Ru(O2CMes)2(p-cymene)] - THF NR[b] 
12 [Ru(O2CMes)2(p-cymene)] - tAmOH NR 
13 [Ru(O2CMes)2(p-cymene)] - 1,2-DCE NR 
14 [Ru(OPiv)2(p-cymene)] - 1,4-dioxane 76 
15 [Ru(O2C1-Ad)2(p-cymene)] - 1,4-dioxane 90 
16 [Ru(O2CMes)2(p-cymene)] - 1,4-dioxane NR[c] 
17 [Ru(O2CMes)2(p-cymene)] MesCO2H 1,4-dioxane 57 
18 [Ru(O2CMes)2(p-cymene)] - PhMe 66[d] 
19 [Ru(O2CMes)2(p-cymene)] - Benzene 58[e] 
20 [Ru(O2CMes)2(p-cymene)] - o-xylene trace[e] 
21 RuCl3·xH2O MesCO2K 1,4-dioxane 62 
22 [RuCl2(p-cymene)]2 MesCO2K 1,4-dioxane 85 
23 Pd(OAc)2 - 1,4-dioxane NR 
[a] Reaction conditions: 1a (0.25 mmol), 62a (0.25 mmol), [TM] (5.0 mol %), additive (15 mol %), solvent (1.0 mL), 
21 h, N2, 110 °C, 1H NMR yield (1,1,2,2 - tetrachloroethane as the internal standard). [b] at 80 °C. [c] 0.1 mL of H2O 
added to reaction medium. [d] at 120 °C, borylation of solvent and unidentified side product was observed. [e] C–H 
Borylation of solvent observed.  
 
Interestingly, there was no reactivity at all in other solvents (entries 11-13) and aromatic 
solvents delivered undesired products arising from the borylation of the solvent (entries 18-
20). Upon addition of MesCOOH as an additive when employing well defined complex 16 as 
the catalyst, the efficiency of the reaction declined (entry 17). However, upon addition of 
MesCO2K as an additive when RuCl3·xH2O or [RuCl2(p-cymene)]2 were employed (entries 21 
and 22) the desired product was observed. These findings clearly suggested the beneficial 
effect of carboxylates. It is noteworthy that Pd(OAc)2 did not show any catalytic activity (entry 
24). Importantly, the optimized raection conditions are operationally simple and employs 
[Ru(O2CMes)2(p-cymene)] 16 as a single-component C–H activation catalyst (entry 10) 




unlike other metal catalysts used for C–H borylation, which normally work in the presence of 
additives. 
 
4.2 Scope of C(sp2)–H borylation 
With the optimized conditions in hand, we next examined the scope of the C(sp2)–H 
borylation (Scheme 39). Pyridine and pyrazole could be used as directing groups to obtain 
monoborylated products 70 in good yields even with a lower catalyst loading of only 
1.0 mol %. Controlling the site-slectivity in C–H borylations of heterocycles is very difficult 
with other metal catalysts.[72] However, site-selective diborylation was observed in case of 2-
(1H-pyrrol-1-yl)pyridine (1b). 
Furthermore, bis catecholato diboron (B2cat2) (62b) could also be used as the borylating 




Scheme 39: Scope of C(sp2)–H borylation. [a] 1 mol % of 16 





3.4.3 Optimization studies for ruthenium-catalyzed C(sp3)–H borylation  
 
At the outset of our studies, we tested a variety of reaction conditions were screened for the 
envisioned borylation reaction of amine 73a with bis pincolato diboron 62a and (Table 5). 
Initial opyimization were performed by Dr. Suman De Sarkar (Table 5). Commerically 
available [RuCl2(p-cymene)]2 did not give the desired product (Table 5, entry 1). Upon 
addition of NaOAc as an additive the desired product 74aa could be obtained in a low yield 
of 24%. An excess of diboorn reagent 62a (1.5 equiv) is required to achieve a good 
conversion (Table 5, entries 7-10), when compared to C(sp2)–H borylation. Reducing the 
temperature and duration of the reaction gave better selectivity as the formation of undesired 
side products could be avoided (Table  5, entry 4 and entries 7-10). Reducing the catalyst 
loading gave less yield of the the desired product (Table 5, entry 11). 
Table 5: Optimization studies performed by Dr. Suman De Sarkar[a] 
 
 







1 [RuCl2(p-cymene)]2 - 120 1.5 20 0 
2 [RuCl2(p-cymene)]2 NaOAc 120 1.5 20 24 
3 - NaOAc 120 1.5 20 0 
4 [Ru(O2CMes)2(p-cymene)] - 120 1.5 20 72 
5 [Ru(O2CMes)2(p-cymene)] - 120 1.2 20 69 
6 [Ru(O2CMes)2(p-cymene)] - 120 1.2 14 58 











7 [Ru(O2CMes)2(p-cymene)] - 110 1.5 20 73 
8 [Ru(O2CMes)2(p-cymene)] - 100 1.5 20 31 
9 [Ru(O2CMes)2(p-cymene)] - 110 1.5 18 76 
10 [Ru(O2CMes)2(p-cymene)] - 110 1.5 16 79 
11] [Ru(O2CMes)2(p-cymene)] - 110 1.5 20 41[c] 
[a] Reaction conditions: 73a (0.50 mmol), 62a (0.50-0.75 mmol), [Ru] (10 mol %), additive (30 mol%), 1,4-dioxane 
(2.0 mL), under N2 in pressure tube. [b] Isolated yield. [c] 5 mol % Ru-cat 
 
Further optimization studies were performed by me (Table 6). There was no product 
observed in the absence of catalyst (Table 6, entry 1). With insights from optimization of 
C(sp2)–H borylation, various ruthenium(II) carboxylate complexes were screened, which 
gave desired products in fair yields (Table 6, entries 2-4). However, a higher amount of 
catalyst loading was required compared to the C(sp2)–H borylation. Inexpensive RuCl3·xH2O  
was not effective for the desired transformation even in the presence of MesCO2K as an 
additive (Table  6, entries 5 and 6). Carboxylate complexes from other metals, such as 
Pd(OAc)2[73]and Co(OAc)2 were not effective (Table 6, entries 6 and 13). Other ruthenium 
complexes which are normally powerful in C(sp3)–H functionalization, are futile in this case 
(Table 6,entries 8-11). Other boron reagents were employed, to verify the generality of the 
reaction. While HBpin 62c (entry 14), B2neop2 62d (entry 15), pinB-Bdab 62e (Table 6, 
entry 16) did not give encouraging results, employing two equivalents of pinB-Bdan 62f 
(Table 6, entry 17) gave good conversion and the desired product could be isolated in good 
yield (61%). Interestingly, only Bpin from the pinB-Bdan reagent was transferred. 





Table 6: Optimization Studies for C(sp3)–H bond Borylation[a] 
 
 
Entry [TM] (x mol %) T (°C) t [h] Yield [%][b] 
1 - 110 16 NR 
2 [Ru(O2CMes)2 (p-cymene)] (2.5 mol %) 110 20 24 
3 [Ru(O2CAd-1)2 (p-cymene)] (10.0 mol %) 110 16 53 
4 [Ru(OPiv)2 (p-cymene)] (10.0 mol %) 110 16 56 
5 RuCl3·xH2O (10.0 mol %) 110 16 NR 
6 RuCl3·xH2O (10.0 mol %) 110 16 NR[c] 
7 Pd(OAc)2 (3.0 mol %) 110 16 NR 
8 Ru(CO)H2(PPh3)3 (5.0 mol %) 120 16 NR[d] 
9 Ru3(CO)12 (3.3 mol %) 120 16 NR[e] 
10 Ru(CO)H2(PPh3)3 (5.0 mol %) 120 16 NR[d, e] 
11 Ru3(CO)12 (3.3 mol %) 120 16 NR[d, e] 
12 [Ru(O2CMes)2 (p-cymene)] (10.0 mol %) 120 16 NR[f] 
13 Co(OAc)2 (10.0 mol %) 110 16 NR 
14 [Ru(O2CMes)2 (p-cymene)] (10.0 mol %) 110 16 < 4[g] 
15 [Ru(O2CMes)2 (p-cymene)] (10.0 mol %) 110 16 < 10[h] 




Entry [TM] (x mol %) T (°C) t [h] Yield [%][b] 
16 [Ru(O2CMes)2 (p-cymene)] (10.0 mol %) 110 16 < 8[i] 
17 [Ru(O2CMes)2 (p-cymene)] (10.0 mol %) 110 16 61[j] 
18 [RuCl2(p-cymene)]2 (5.0 mol %) 110 16 34[c, k] 
[a] Reaction conditions: 73a (0.50 mmol), 62a (0.75 mmol), [TM] (x mol %), 1,4-dioxane (2.0 mL), under N2 in 
pressure tube, under N2. [b] Isolated yield. [c] MesCO2K (30 mol %). [d] 120°C under N2 atmosphere. [e] Pinacolone 
(2.0 mL) as solvent. [f] PhCMe3 (2.0 mL) as solvent [g] HBpin as the borylating agent. [h] B2neop2 as the borylating 
agent. [i] pinB-Bdab as the borylating agent. [j] pinB-Bdan (2.0 mmol) as the borylating agent [k] GC conversion 
with n-dodecane as internal standard. 
 
3.4.4 Mechanistic investigations for C(sp3)–H borylation 
We performed several experiments to get an insight into the reaction mechanism. During 
kinetic studies for the borylation of 73a under standard conditions, we observed a significant 
induction period of 7-10 h. Long induction periods and irreproducible rates are known in 
literature for borylation reactions.[74] The reaction was not completely shut down on 
employing typical radical scavengers such as TEMPO and galvinoxyl, for the reaction 
between 62a and 73a, which is contrary to the observation made by Kuninobu and 
coworkers in an analogous palladium-catalyzed reaction (Scheme 40a).[75] We then 
speculated the formation of imine from amine 73a, as the reason for long induction period. 
However, analysis of reaction mixtures by GC/GC-MS did not show any evidence for the 
imine as an intermediate. Formation of a black coating in the reaction tubes at the end of the 
reaction, prompted us to verify if the catalysis is heterogenous in nature. The mercury test[76] 
did not show any detrimental effect on the efficacy of the reaction with a 81% GC yield 
(Scheme 40b). The observation is similar for mercury test performed for reaction between 
benzo[h]quinoline (1a) and 62a. (79% 1H NMR yield). Interestingly, 11B NMR studies for 
stoichiometric reaction between 62a and 16 showed that the resonance corresponding to 
62a completely disappeared and a new signal at 21 ppm appeared. On addition of 73a to 
this mixture, the formation of product 74aa was observed (16% GC yield) (Scheme 40c). 
 





Scheme 40: Mechanistic investigations on C(sp3)–H borylation. [a] GC yield with n-dodecane 
as the internal standard. 




3.4.5 Mechanistic investigations for C(sp2)–H bond borylation 
To get insights in the mechanism of C(sp2)–H bond borylation, cycloruthenated complex[77] 
82 was synthesized and was probed as a catalyst in the C–H borylation. Interestingly, 
complex 82 was catalytically competent and the desired product was obtained in 82% yield 
(Scheme 41). This result suggested that complex 82 is most likely the intermediate involved 
in the catalytic cycle. 
 
 
Scheme 40: Reaction with cycloruthenated complex 82 as catalyst 
 
3.4.6 Limitations of C(sp2)–H borylation 
Investigations with other directing groups employing the optimized reaction conditions for the 
C(sp2)–H borylation did not lead to any borylated products (Figure 11). 
 
 
Figure 11: As of yet unsuccessful substrates for C(sp2)–H borylations 





3.4.7 Limitations of C(sp3)–H borylation: 
Variation of the directing group in order to understand the reactivity pattern illustrated the 
superiority of pyridine as a directing group for C(sp3)–H  borylations (Figure 12). 
 
Figure 12: Thus far unsuccessful directing groups for C(sp2)–H borylations 
 
 





Summary and Outlook  
In the last decades ruthenium(II)-catalyzed C−H functionalizations have emerged as a 
reliable tool for the efficient chemo- and site-selective construction of C−C and C−X bonds in 
an atom and step-economic fashion. Within this thesis, efforts have been devoted to develop 
new synthetic methods to achieve the formation of C−C and C−B bonds using carboxylate-
assisted ruthenium(II) catalysis. 
In the first part of this thesis, direct C–H arylation of arenes was achieved using tetrazole as 
the directing group under carboxylate-assisted ruthenium(II) catalysis. A broad substrate 
scope was achieved using various aryl bromides and aryl pseudohalides. Importantly, our 
robust reaction conditions employed a single-component catalyst and toluene as the solvent 
to guarantee robust C–H functionalizations with remarkable selectivity.[78] Thus, a carboxylic 
acid derived ruthenium (II) catalyst enabled syntheses of biaryl tetrazoles, key structural 
motifs in various angiotensin II receptor blockers.[79] This paved the way for a more 
appealing catalytic system in the Ackermann group recently.[80] 
 
 
Scheme 43: Ruthenium-Catalyzed C(sp2)–H Arylation 
 
In the second part of this thesis, arylation of C(sp3)–H bonds was achieved employing well-
defined ruthenium(II) biscarboxylate complexes.[81] Variation of the removable directing 
group was examined and the importance of the Lewis basic directing group was established. 
Ample scope with various aryl and heteroaryl bromides was achieved. Detailed mechanistic 
studies provided strong evidence for an initial, reversible C(sp3)–H bond activation. 





Scheme 44: Ruthenium-Catalyzed C(sp3)–H Arylation 
 
In the third part of this thesis, carboxylic acids were used as traceless directing groups to 
achieve redox-neutral hydroarylation of alkynes.[82] The scope with various internal alkynes 
and differently-substituted acids was studied. Key features of this highly useful method 
obviate the use of an external base and expensive silver salts. Moreover, removal of the 
directing group occurs in a domino fashion.83 Further developments of this method to 
synthesize various compounds of pharmacological importance are currently under 
investigation in the Ackermann group. 





Scheme 45: Ruthenium(II) Catalyzed Decarboxylative Hydroarylation 
 
In the fourth part of this thesis, chelation-assisted borylation of C(sp3)–H and C(sp2)–H 
bonds was achieved using ruthenium(II) biscarboxylate complexes. Stable diboron reagents 
such as B2pin2 and B2cat2 were the borylation agents of choice. Importantly, this method 
does not require any external base or oxidant, and occurs at relatively mild conditions. This 
economically attractive method allows for the preparation of highly useful pinacol boronate 
esters in an atom- and step-economic fashion and proves the unique power of ruthenium(II) 
biscarboxylate complexes over other ruthenium catalysts. 
 













5.1 General Remarks 
Unless otherwise noticed, all reactions were performed under N2 atmosphere using pre-dried 
glassware and standard Schlenk techniques. Syringes and needles for handling dry solvents 
or liquid reagents were washed with N2 three times prior to their use. 
 
Solvents 
All solvents for reactions involving moisture-sensitive reagents were dried, distilled and 
stored under inert atmosphere (argon or nitrogen) according to the following standard 
procedures. 
 
tert-Amyl alcohol (t-AmOH) was used stirred over sodium chips for 5 h at 120 °C and distilled 
under ambient pressure. 
Water (H2O) was degassed before its use applying repeated Freeze-Pump-Thaw degassing 
procedure. 
1,2-dichloroethane (DCE) was dried over CaH2 for 8 h, degassed and distilled under 
reduced pressure. 
N,N-dimethylformamide (DMF) was dried over CaH2 for 8 h, degassed and distilled under 
reduced pressure. 
Acetonitrile (MeCN) was dried over CaH2 for 8 h, degassed and distilled under reduced 
pressure. 
Dimethylacetamide (DMA) was dried over CaH2 for 8 h, degassed and distilled under 
reduced pressure. 
Dichloromethane (DCM) was purified using a solvent purification system (SPS) from 
MBRAUN SPS-800. 
Tetrahydrofuran (THF) was purified using a solvent purification system (SPS) from MBRAUN 
SPS-800. 
N-methyl-2-pyrrolidone (NMP) was stirred over CaH2 for 4 h at 150 °C and subsequently 





Methanol (MeOH) was stirred over magnesium for three hours at 65 °C prior to distillation. 
Toluene (PhMe) was either pre-dried over KH followed by distillation from sodium/ 
benzophenone. 
1,4-dioxane was dried by distillation from sodium/benzophenone. 




The following pressures were measured on the used vacuum pump and were not corrected: 
membrane pump vacuum (MPV): 0.5 mbar, oil pump vacuum (OPV): 0.1 mbar. 
 
Melting Points (M. p.) 
Melting points were measured using a Stuart® Melting Point Apparatus SMP3. Reported 
values are uncorrected. 
 
Chromatography 
Analytical thin layer chromatography (TLC) was performed on 0.25 mm silica gel 60F-plates 
(MACHEREY-NAGEL) with 254 nm fluorescent indicator from MERCK. TLC plates were 
visualized under UV-light or developed by treatment with basic KMnO4 solution followed by 
heating. Chromatographic purification of products was accomplished by flash column 
chromatography on MERCK silica gel, grade 60 (0.040–0.063 mm). 
 
Gas Chromatograpghy (GC) 
The conversion of the reactions was monitored applying coupled gas chromatography/mass 
spectrometry using G1760C GCDplus with mass detector HP 5971, 5890 Series II with mass 
detector HP 5972 from HEWLETT-PACKARD and 7890A GC-System with mass detector 
5975C (Triplex-Axis-Detector) from AGILENT TECHNOLOGIES equipped with HP-5MS 







Recycling preparative HPLC was performed on a system from JAI (LC-92XX II Series, 
Injection- and Control-Valve, UV and RI Detector) connected to JAIGEL HH series columns. 
Chloroform (ethanol stabilized) of HPLC grade was employed. 
 
Nuclear Magnetic Resonance Spectroscopy (NMR) 
Nuclear magnetic resonance (NMR) spectroscopy was performed at 300, 400, 500 or 600 
MHz (1H-NMR), 75 or 125 MHz (13C-NMR, APT) and 283 MHz (19F-NMR) on BRUKER AM 
250, VARIAN Unity-300 and Inova 500 instruments. Chemical shifts are reported as δ-values 
in ppm relative to the residual proton resonance of the deuterated solvent or its carbon atom, 
respectively, or the standard trimethylsilyl (TMS) peak. For characterization of the observed 
resonance multiplicities the following abbreviations were applied: s (singlet), d (doublet), t 
(triplet), q (quartet), m (multiplet), dd (doublet of doublet), dt (doublet of triplet), or analogue 
representations. The coupling constants J are reported in Hertz (Hz). 
 
Infrared Spectroscopy (IR) 
Infrared spectra were recorded on a BRUKER Alpha-P ATR-spectrometer. Liquid probes 
have been measured as film and solid probes neat. Analysis of the spectral data has been 
done by using the OPUS 6 software from BRUKER, respectively OPUS 6. Absorption (ṽ) is 
given in wave number (cm–1). Spectra were recorded in the range of 4000 to 400 cm–1. 
 
Mass Spectrometry (MS) 
MS (EI) and HR-MS (EI) were measured on a Time-of-Flight mass spectrometer AccuTOF 
from JOEL. ESI-mass spectra were recorded on an Ion-Trap mass spectrometer LCQ from 
FINNIGAN or on a Time-of-Flight mass spectrometer microTOF from BRUKER. ESI-HR-MS 
spectra were recorded on a BRUKER APEX IV or a BRUKER DALTONIC {7T, Fourier 
Transform Ion Cyclotron Resonance (FTICR)} mass spectrometer. The ratios of mass to 







Chemicals obtained from commercial sources were used without further purification. 
Tetrazoles (15) are prepared according to described literature procedures.[84] 
The following compounds were obtained by the generous courtesy of the persons named 
below: 
[RuCl2(p-cymene)]2, [RuBr2(p-cymene)]2, [Ru(O2CMes)2(p-cymene)] 16, [Ru(OPiv)2(p-
cymene)] by courtesy of Karsten Rauch. 
2-(1H-pyrrol-1-yl)pyridine (1b), 2-(4-methoxyphenyl)pyridine (1e) by courtesy of Dr. Jie Li. 
N-benzyl-3-methylpyridin-2-amine (27a), N-benzylpyridin-2-amine (27b), N-benzyl-3-
methoxypyridin-2-amine (27c) and 2-(benzyloxy)-3-methylpyridine (27f) by courtesy of Jordi 
Creus. 
3-methyl-2-(piperidin-1-yl)pyridine (73b), 2-(3-methylpyridin-2-yl)-1,2,3,4-
tetrahydroisoquinoline (73c), 2-(pyrrolidin-1-yl)pyrimidine (73d), N,N-diethylpyridin-2-amine 
(73f) by courtesy of Kris Bielefeld. 
di(4-methylphenyl)acetylene (34b), 1,2-bis(4-methoxyphenyl)ethyne (34c) by courtesy of 
Dr. Sebastian Lackner. 
N-benzyl-3-phenylpyridin-2-amine (27d), N-benzyl-3-methylquinolin-2-amine (27g), N-(furan-
2-ylmethyl)-3-methylpyridin-2-amine (27h), 3-methyl-N-(thiophen-2-ylmethyl)pyridin-2-amine 
(27i) by courtesy of Daniel Zell 
N-benzyl-3-(trifluoromethyl)pyridin-2-amine (27e) by courtesy of Rajkumar Jeyachandran 
3-methyl-2-(pyrrolidin-1-yl)pyridine (73a) by courtesy of Dr. Marvin Schinkel 
phenyl diethylcarbamate (40) by courtesy of Dr. Weiping Liu 
1-(o-tolyl)-1H-pyrazole (1c) by courtesy of Keshav Raghuvanshi 
2-(3,4-dihydroisoquinolin-2(1H)-yl)benzo[d]oxazole (73e) by courtesy of Marcus Thater 






5.2. General procedures 
General Procedure A: Ruthenium(II)-catalyzed C–H arylations of phenyl 
tetrazoles 
 
[RuCl2(p-cymene)]2 (15.3 mg, 0.025 mmol, 5.0 mol %), MesCO2H (24.6 mg, 0.15 mmol, 
30 mol %), tetrazoles 15 (0.50 mmol, 1.0 equiv), aryl bromides 2 (0.6 mmol, 1.2 equiv) and 
K2CO3 (138 mg, 1.00 mmol) were placed in a 25 mL Schlenk tube. The tube was evacuated 
and flushed with N2 three times, PhMe (2 mL) (and if liquid, aryl bromide was also added at 
this point) was added. The reaction mixture was stirred for 18 h at 120 °C. Then, H2O 
(50 mL) was added at ambient temperature. The aqueous layer was extracted with CH2Cl2 
(3×40 mL), the combined organic layers were washed with brine (50 mL), dried over 
Na2SO4, and concentrated in vacuo. The remaining residue was purified by column 
chromatography on silica gel (n-hexane/EtOAc). 
General Procedure B: Ruthenium(II)-catalyzed C(sp3)–H arylations: 
 
[Ru(O2CMes)2(p-cymene)] (16) (14 mg, 0.025 mmol, 5.0 mol %), benzyl amines 27 
(0.50 mmol, 1.0 equiv), Na2CO3 (159 mg, 1.50 mmol, 3.0 equiv) were placed in a 25 mL 
Schlenk tube. The tube was evacuated and flushed with N2 three times, o-xylene (2 mL) and 
aryl bromides 2 (0.75 mmol, 1.5 equiv) was added. The reaction mixture was stirred at 
140 °C for 24 h. At ambient temperature, the suspension was filtered through a short pad of 
Celite®, which was further washed with CH2Cl2 (50 mL). All the volatiles were removed in 
vacuo and the residue was purified by column chromatography on silica gel (n-
hexane/EtOAc). 
General Procedure C: Decarboxylative Hydroarylation of alkynes 
 
[Ru(O2CMes)2(p-cymene)] (16) (28.0 mg, 0.05 mmol, 10 mol %), benzoic acids 48 
(1.00 mmol, 2.0 equiv) and alkynes 34 (0.50 mmol, 1.0 equiv) were placed in a pre-dried 
pressure tube equipped with a rubber septum. The tube was evacuated and flushed with N2 
three times and either PhMe (2.0 mL) or DCE (2.0 mL) was added. The rubber septum was 
replaced by the pressure tube screw cap and the reaction mixture was stirred at 100 °C for 
24 h. At ambient temperature, all volatiles were removed in vacuo and the residue was 






General Procedure D: Ruthenium(II)-catalyzed C(sp2)–H borylations 
 
[Ru(O2CMes)2(p-cymene)] (16) (14.0 mg, 0.025 mmol, 5 mol %), arenes 1 (0.50 mmol, 
1.0 equiv) and B2pin2 2a (0.50 mmol, 1.0 equiv) were placed in a pre-dried pressure tube 
equipped with a rubber septum. The tube was evacuated and flushed with N2 three times 
and 1,4-dioxane (2.0 mL) was added. The rubber septum was replaced by the pressure tube 
screw cap and the reaction mixture was stirred at 110 °C for 20 h. At ambient temperature, 
all volatiles were removed in vacuo and the residue was purified by column chromatography 
on silica gel (n-hexane/EtOAc/NEt3). 
 
General Procedure E: Ruthenium-catalyzed C(sp3)–H borylations 
 
[Ru(O2CMes)2(p-cymene)] (16) (28.0 mg, 0.05 mmol, 10 mol %), Amine 1a (0.50 mmol, 
1.0 equiv) and B2pin2 2a (0.75 mmol, 1.5 equiv) were placed in a pre-dried pressure tube 
equipped with a rubber septum. The tube was evacuated and flushed with N2 three times 
and 1,4-dioxane (2.0 mL) was added. The rubber septum was replaced by the pressure tube 
screw cap and the reaction mixture was stirred at 110 °C for 16 h. At ambient temperature, 
all volatiles were removed in vacuo and the residue was purified by column chromatography 






5.3 Ruthenium(II)-catalyzed C–H arylations of phenyl tetrazoles 






The general procedure A was followed using 15a (118 mg, 0.50 mmol) and 2b (109 mg, 
0.55 mmol). Compound 71ab (117 mg, 66%) was obtained as a colorless liquid after 
purification by column chromatography on silica gel (n-hexane/EtOAc 5:1). 
 
1H NMR (300 MHz, CDCl3): δ = 7.85 (d, J = 7.6 Hz, 1H), 7.76 (s, 1H), 7.66 (dd, J = 7.5, 
1.5 Hz, 1H), 7.59 (d, J = 7.9 Hz, 1H), 7.48 (td, J = 7.5, 1.4 Hz, 1H), 7.40–7.05 (m, 6H), 6.76 
(d, J = 6.8 Hz, 2H), 4.87 (s, 2H), 2.49 (s, 3H).  
 
13C NMR (75 MHz, CDCl3): δ = 197.4 (Cq), 154.3 (Cq), 140.8 (Cq), 139.1 (Cq), 137.4 (Cq), 
133.1 (CH), 132.8 (Cq), 131.9 (CH), 131.1 (CH), 130.3 (CH), 129.1 (CH), 128.7 (CH), 128.6 
(CH), 128.5 (CH), 128.2 (CH), 127.7 (CH), 127.6 (CH), 122.6 (Cq), 50.9 (CH2), 26.6 (CH3). 
 
IR (ATR): 1682, 1405, 1357, 1227, 1100, 758 cm−1. 
 
MS (EI) m/z (relative intensity): 354 ([M+] 28), 353 (41), 326 (21), 325 (68), 91 (100). 
 











The general procedure A was followed using 15b (136 mg, 0.51 mmol) and 2c (109 mg, 
0.55 mmol). Compound 71bc (121 mg, 62%) was obtained as a white solid after purification 
by column chromatography on silica gel (n-hexane/EtOAc 5:1). 
 
Mp: 117–119 °C. 
 
1H NMR (300 MHz, CDCl3): δ = 7.84–7.77 (m, 2H), 7.67 (td, J = 7.6, 1.4 Hz, 1H), 7.58 (dd, 
J = 7.8, 1.4 Hz, 1H), 7.50 (td, J = 7.5, 1.4 Hz, 1H), 7.36 (dd, J = 7.7, 1.4 Hz, 1H), 7.21–7.12 
(m, 2H), 6.68–6.61 (m, 4H), 4.81 (s, 2H), 3.72 (s, 3H), 2.57 (s, 3H). 
 
13C NMR (75 MHz, CDCl3): δ = 197.4 (Cq), 159.7 (Cq), 153.9 (Cq), 143.3 (Cq), 140.7 (Cq), 
136.2 (Cq), 131.6 (CH), 131.2 (CH), 130.2 (CH), 129.2 (CH), 128.9 (CH), 128.8 (CH), 128.7 
(CH), 128.5 (CH), 124.8 (Cq), 122.8 (Cq), 114.0 (CH), 55.2 (CH3), 50.5 (CH2), 26.6 (CH3). 
 
IR (ATR): 1677, 1513, 1400, 1326, 1244, 1179, 1100, 1034, 775 cm−1. 
 











The general procedure A was followed using 15c (136 mg, 0.51 mmol) and 2c (109 mg, 
0.60 mmol). Compound 71cc (108 mg, 57%) was obtained as a green solid after purification 
by column chromatography on silica gel (n-hexane/EtOAc 5:1). 
 
Mp: 153–154 °C. 
 
1H NMR (300 MHz, CDCl3): δ = 7.80 (d, J = 8.3 Hz, 2H), 7.29 (d, J = 8.5 Hz, 1H), 7.24–7.09 
(m, 5H), 7.05 (d, J = 2.6 Hz, 1H), 6.99 (dd, J = 8.5, 2.6 Hz, 1H), 6.79 (d, 2H), 4.87 (s, 2H), 
3.90 (s, 3H), 2.56 (s, 3H). 
 
13C NMR (75 MHz, CDCl3): δ = 197.3 (Cq), 161.8 (Cq), 154.1 (Cq), 143.3 (Cq), 142.2 (Cq), 
136.2 (Cq), 132.9 (Cq), 132.6 (CH), 128.8 (CH), 128.7 (CH), 128.6 (CH), 128.5 (CH), 127.6 
(CH), 115.9 (CH), 114.4 (Cq), 113.8 (CH), 55.6 (CH3), 50.7 (CH2), 26.6 (CH3). 
 
IR (ATR): 1677, 1601, 1467, 1444, 1268, 1221, 848 cm−1. 
 











The general procedure A was followed using 15d (127 mg, 0.50 mmol) and 2c (109 mg, 
0.55 mmol). Compound 71dc (104 mg, 56%) was obtained as a white solid after purification 
by column chromatography on silica gel (n-hexane/EtOAc 5:1). 
 
Mp: 149–151 °C. 
 
1H NMR (300 MHz, CDCl3): δ = 7.82 (d, J = 8.6 Hz, 2H), 7.36 (dt, J = 1.5, 0.8, 0.8 Hz, 1H), 
7.32–7.06 (m, 7H), 6.80–6.74 (m, 2H), 4.85 (s, 2H), 2.56 (s, 3H), 2.48 (s, 3H). 
 
13C NMR (125 MHz, CDCl3): δ = 197.4 (Cq), 154.3 (Cq), 143.6 (Cq), 142.0 (Cq), 140.6 (Cq), 
136.2 (Cq), 132.9 (Cq), 131.1 (CH), 130.1 (CH), 129.3 (CH), 128.9 (CH), 128.8 (CH), 128.7 
(CH), 128.6 (CH), 127.7 (CH), 119.7 (Cq), 50.8 (CH2), 26.6 (CH3), 21.5 (CH3). 
 
IR (ATR): 1675, 1601, 1495, 1453, 1268, 1229, 833 cm−1. 
 










The general procedure A was followed using 15a (119 mg, 0.50 mmol) and 2c (109 mg, 
0.60 mmol). Compound 71ac (116 mg, 64%) was obtained as a white solid after purification 
by column chromatography on silica gel (n-hexane/EtOAc 2:1). 
 
Mp: 157–159 °C. 
 
1H NMR (300 MHz, CDCl3): δ = 7.87–7.78 (m, 2H), 7.67 (td, J = 7.7, 1.4 Hz, 1H), 7.57 (dd, 
J = 7.7, 1.4 Hz, 1H), 7.49 (td, J = 7.7, 1.4 Hz, 1H), 7.37 (dd, J = 7.7, 1.4 Hz, 1H), 7.24–7.09 
(m, 5H), 6.85–6.69 (m, 2H), 4.88 (s, 2H), 2.58 (s, 3H). 
 
13C NMR (75 MHz, CDCl3): δ = 197.4 (Cq), 154.2 (Cq), 143.3 (Cq), 140.7 (Cq), 136.3 (Cq), 
132.8 (Cq), 131.7 (CH), 131.2 (CH), 130.3 (CH), 128.9 (CH), 128.8 (CH), 128.7 (CH), 128.7 
(CH), 128.5 (CH), 127.7 (CH), 122.7 (Cq), 51.0 (CH2), 26.6 (CH3). 
 
IR (ATR): 1680, 1496, 1437, 1402, 1357, 1265, 959, 849, 721, 700 cm−1. 
 
MS (EI) m/z (relative intensity): 354 (12), 353 (35), 325 (10), 206 (8), 192 (8), 179 (8), 164 
(11), 151 (6), 91 (100), 65 (15), 43 (38). 
 








1-Benzyl-5-(4′-methyl-[1, 1′-biphenyl]-2-yl)-1H-tetrazole (71ad) 
 
The general procedure A was followed using 15a (118 mg, 0.50 mmol) and 2d (97 mg, 
0.57 mmol). Compound 71ad (82 mg, 50%) was obtained as a colorless solid after 
purification by column chromatography on silica gel (n-hexane/EtOAc 6:1). 
 
Mp: 143–144 °C. 
 
1H NMR (300 MHz, CDCl3): δ = 7.67–7.52 (m, 2H), 7.45–7.30 (m, 2H), 7.23–7.06 (m, 5H), 
7.06–7.00 (m, 2H), 6.81–6.64 (m, 2H), 4.77 (s, 2H), 2.34 (s, 3H). 
 
13C NMR (75 MHz, CDCl3): δ = 154.7 (Cq), 141.6 (Cq), 138.0 (Cq), 135.9 (Cq), 133.1 (Cq), 
131.5 (CH), 131.2 (CH), 130.1 (CH), 129.7 (CH), 128.6 (CH), 128.5 (CH), 128.4 (CH), 127.8 
(CH), 127.5 (CH), 122.6 (Cq), 50.8 (CH2), 21.1 (CH3). 
 
IR (ATR): 1597, 1495, 1470, 1457, 1240, 1074, 756 cm−1. 
 











The general procedure A was followed using 15a (118 mg, 0.50 mmol) and 2e (136 mg, 
0.60 mmol). Compound 71ae (140 mg, 69%) was obtained as a colorless liquid after 
purification by column chromatography on silica gel (n-hexane/EtOAc 4:1). 
 
1H NMR (300 MHz, CDCl3): δ = 7.67–7.57 (m, 2H), 7.42 (ddd, J = 7.8, 6.1, 2.5 Hz, 1H), 
7.36–7.31 (m, 1H), 7.24–7.09 (m, 3H), 6.81–6.72 (m, 2H), 6.34 (s, 2H), 4.84 (s, 2H), 3.83 (s, 
3H), 3.67 (s, 6H). 
 
13C NMR (75 MHz, CDCl3): δ = 154.8 (Cq), 153.3 (Cq), 141.4 (Cq), 137.8 (Cq), 133.1 (Cq), 
132.9 (Cq), 131.6 (CH), 131.2 (CH), 129.8 (CH), 128.6 (CH), 128.5 (CH), 127.7 (CH), 127.6 
(CH), 122.5 (Cq), 105.7 (CH), 60.9 (CH3), 56.1 (CH3), 50.7 (CH2). 
 
IR (film): 1584, 1568, 1508, 1470, 1455, 1240, 1122, 1001, 763. 
 











The general procedure A was followed using 15a (118 mg, 0.50 mmol) and 2f (110 mg, 
0.57 mmol). Compound 71af (78 mg, 45%) was obtained as a colorless liquid after 
purification by column chromatography on silica gel (n-hexane/EtOAc 5:1). 
 
1H NMR (300 MHz, CDCl3): δ = 7.64 (td, J = 7.5, 1.4 Hz, 1H), 7.54–7.40 (m, 2H), 7.33 (dd, 
J = 8.0, 1.4 Hz, 1H), 7.27–7.10 (m, 3H), 6.85–6.73 (m, 2H), 6.66 (tt, J = 8.8, 2.3 Hz, 1H), 
6.58–6.40 (m, 2H), 5.04 (s, 2H). 
 
13C NMR (125 MHz, CDCl3): δ = 162.7 (Cq, JC–F = 250, 13 Hz), 153.8 (Cq), 141.8(Cq, JC–
F = 9 Hz), 139.8 (Cq, JC–F = 2 Hz), 132.8 (Cq), 131.6 (CH), 130.1 (CH), 130.2 (CH), 128.8 
(CH), 128.7 (CH), 128.6 (CH), 127.6 (CH), 122.7 (Cq), 111.71 (CH, JC–F = 20, 7 Hz), 103.4 
(CH, JC–F = 25 Hz), 50.1 (CH2). 
 
19F NMR (282 MHz, CDCl3): δ = −(108.16–108.33) (m). 
 
IR (film): 1622, 1593, 1497, 1406, 1099, 987, 860, 689 cm−1. 
 
MS (EI) m/z (relative intensity): 348 ([M+] 38), 347 (48), 319 (32), 201 (48), 91 (100). 
 












The general procedure A was followed using 15a (118 mg, 0.50 mmol) and 2g (98 mg, 
0.62 mmol) Compound 71ag (46 mg, 30%) was obtained as a green liquid after purification 
by column chromatography on silica gel (n-hexane/EtOAc 5:1). 
 
1H NMR (300 MHz, CDCl3): δ = 8.49 (d, J = 4.6 Hz, 1H), 8.39 (s, 1H), 7.67 (t, J = 7.6 Hz, 
1H), 7.59–7.44 (m, 2H), 7.40–7.04 (m, 6H), 6.78 (d, J = 7.0 Hz, 2H), 4.97 (s, 2H). 
 
13C NMR (125 MHz, CDCl3): δ = 153.7 (Cq), 148.9 (CH), 148.8 (CH), 138.3 (Cq), 135.8 (CH), 
134.3 (Cq), 132.6 (Cq), 131.6 (CH), 130.8 (CH), 130.3 (CH), 128.6 (CH), 128.5 (CH), 128.4 
(CH), 127.5 (CH), 122.8 (CH), 122.7 (Cq), 50.9 (CH2). 
 
IR (film): 1603, 1404, 1274, 1247, 1026, 791, 761. 
 










The general procedure A was followed using 15a (118 mg, 0.50 mmol) and 2h (99 mg, 
0.60 mmol). Compound 71ah (101 mg, 63%) was obtained as a white solid after purification 
by column chromatography on silica gel (n-hexane/EtOAc 6:1). 
 
Mp: 90–92 °C. 
 
1H NMR (300 MHz, CDCl3): δ = 7.65 (dd, J = 8.0, 1.0 Hz, 1H), 7.59–7.53 (m, 1H), 7.39–7.08 
(m, 6H), 6.90 (dd, J = 5.1, 3.6 Hz, 1H), 6.84–6.76 (m, 2H), 6.59 (dd, J = 3.6, 1.2 Hz, 1H), 
4.90 (s, 2H). 
 
13C NMR (75 MHz, CDCl3): δ = 154.2 (Cq), 140.1 (Cq), 134.4 (Cq), 132.9 (Cq), 131.5 (CH), 
131.4 (CH), 130.0 (CH), 128.7 (CH), 128.5 (CH), 128.2 (CH), 127.9 (CH), 127.8 (CH), 127.0 
(CH), 126.9 (CH), 122.2 (Cq), 50.9 (CH2). 
 
IR (ATR): 1494, 1470, 1457, 1240, 1159, 1098, 1074, 756 cm−1. 
 
MS (EI) m/z (relative intensity): 318 ([M+] 28), 317 (53), 289 (30), 91 (100). 
 





5.4 Ruthenium(II)-catalyzed C(sp3)–H arylation 





The representative procedure B was followed using N-Benzyl-3-methylpyridin-2-amin (27a) 
(99 mg, 0.50 mmol, 1.0 equiv), and bromobenzene (2i) (118 mg, 0.75 mmol). Purification by 
column chromatography on silica gel (n-hexane/EtOAc 99/1 → 98/2) yielded 29ai (95 mg, 
69%) as a colorless solid. 
 
M.p: 91–93 °C. 
 
1H-NMR (300 MHz, CDCl3): δ = 7.98 (dd, J = 5.2, 1.7 Hz, 1H), 7.39–7.21 (m, 11H), 6.59–
6.48 (m, 2H), 4.67 (d, J = 7.0 Hz, 1H), 2.15 (s, 3H). 
 
13C-NMR (75 MHz, CDCl3): δ = 155.6 (Cq), 145.6 (CH), 143.5 (Cq), 136.9 (CH), 128.4 (CH), 
127.5 (CH), 126.1 (CH), 116.3 (Cq), 113.1 (CH), 58.4 (CH), 17.0 (CH3). 
 
IR (neat): 3438, 1595, 1485, 1465, 1057, 695 cm-1. 
 
MS (EI) m/z (relative intensity): 274 ([M+], 87), 182 (55), 167 (100), 165 (52), 98 (50), 43 
(69). 
 
HR-MS (EI) m/z calcd for C19H18N2+ 274.1470, found 274.1462. 
 











The representative procedure B was followed using N-benzyl-3-phenylpyridin-2-amine (27d) 
(130 mg, 0.50 mmol) and bromobenzene (2i) (118 mg, 0.75 mmol). Purification by column 
chromatography on silica gel (n-hexane/EtOAc 99/1 → 98/2) yielded 29di (34 mg, 20%) as a 
colorless solid. 
 
M.p: 90–92 °C. 
 
1H-NMR (300 MHz, CDCl3): δ = 8.08 (dd, J = 5.1, 1.8 Hz, 1H), 7.48–7.16 (m, 16H), 6.65 (dd, 
J = 7.3, 5.0 Hz, 1H), 6.52 (d, J = 7.5 Hz, 1H), 5.20 (d, J = 7.5 Hz, 1H). 
 
13C-NMR (125 MHz, CDCl3): δ = 154.4 (Cq), 147.2 (CH), 143.3 (Cq), 137.9 (Cq), 137.1 (CH), 
129.2 (CH), 128.8 (CH), 128.4 (CH), 127.8 (CH), 127.4 (CH), 126.9 (CH), 122.2 (Cq), 113.2 
(CH), 58.5 (CH). IR (neat): 3447, 3023, 1596, 1463, 1280, 767, 696 cm-1. 
 
MS (EI) m/z (relative intensity): 336 ([M+], 100), 335 (20), 182 (45), 167 (87), 165 (45). 
 
HR-MS (EI) m/z calcd for C24H20N2+ 336.1626, found 336.1629. 
 








The representative procedure B was followed using N-benzyl-3-(trifluoromethyl)pyridin-2-
amine (27e) (126 mg, 0.50 mmol) and bromobenzene (2i) (118 mg, 0.75 mmol). Purification 
by column chromatography on silica gel (n-pentane/EtOAc 50/1 → 40/1 → 30/1) yielded 
29ei (78 mg, 48%) as a yellow oil. 
 
1H-NMR (300 MHz, CDCl3): δ = 8.20 (ddd, J = 5.0, 1.9, 1.0 Hz, 1H), 7.67 (ddd, J = 7.6, 1.8, 
0.8 Hz, 1H), 7.38–7.15 (m, 9H), 6.70–6.46 (m, 2H), 5.46 (d, J = 6.5 Hz, 1H). 
 
13C-NMR (125 MHz, CDCl3): δ = 153.5 (Cq), 151.8 (CH), 142.6 (Cq), 134.9 (CH, J = 10.3 Hz), 
128.6 (CH), 127.4 (CH), 127.2 (CH), 124.5 (Cq, J = 273.9 Hz), 111.9 (CH), 58.4 (CH). 
 
19F-NMR (282 MHz, CDCl3): δ = –63.7 (s). 
 
IR (neat): 3476, 1602, 1582, 1493, 1465, 1301, 1102, 1024, 697 cm-1. 
 
MS (EI) m/z (relative intensity): 328 ([M+], 90), 251 (25), 182 (45), 167 (100), 152 (35), 128 
(30), 104 (20), 77 (15). 
 
HR-MS (EI) m/z calcd for C19H15F3N2+ 328.1187, found 328.1176. 
 









The representative procedure B was followed using N-benzyl-3-methylpyridin-2-amine (27a) 
(99 mg, 0.50 mmol) and 1-bromo-4-methylbenzene (2d) (128 mg, 0.75 mmol). Purification 
by column chromatography on silica gel (n-hexane/EtOAc 99/1 → 98/2) yielded 29ad 
(90 mg, 62%) as a colorless solid. 
 
M.p. = 103–105 °C. 
 
1H-NMR (300 MHz, CDCl3): δ = 7.95 (dd, J = 5.1, 1.7 Hz, 1H), 7.36–7.09 (m, 10H), 6.55–
6.46 (m, 2H), 4.63 (d, J = 7.0 Hz, 1H), 2.31 (s, 3H), 2.12 (s, 3H). 
 
13C-NMR (75 MHz, CDCl3): δ = 155.7 (Cq), 145.6 (CH), 143.6 (Cq), 140.5 (Cq), 136.9 (CH), 
136.6 (Cq), 129.2 (CH), 128.4 (CH), 127.5 (CH), 127.4 (CH), 126.9 (CH), 116.3 (Cq), 112.9 
(CH), 58.2 (CH), 21.0 (CH3), 17.1 (CH3). 
 
IR (neat): 3446, 3024, 1597, 1464, 771, 696 cm-1. 
 
MS (EI) m/z (relative intensity): 288 ([M+], 75), 196 (33), 181 (100), 210 (35), 166 (38), 165 
(40). 
 
HR-MS (EI) m/z calcd for C20H20N2+ 288.1626, found 288.1637. 
 











The representative procedure B was followed using N-benzyl-3-methylpyridin-2-amine (27a) 
(99 mg, 0.50 mmol) and 1-bromo-4-methoxybenzene (2j) (140 mg, 0.75 mmol). Purification 
by column chromatography on silica gel (n-hexane/EtOAc 99/1 → 98/2) yielded 29aj 
(105 mg, 69%) as a colorless solid. 
 
M.p. = 60–62 °C. 
 
1H-NMR (300 MHz, CDCl3): δ = 7.95 (dd, J = 5.1, 1.7 Hz, 1H), 7.34–7.16 (m, 8H), 6.87–6.79 
(m, 2H), 6.54–6.43 (m, 2H), 4.60 (d, J = 7.0 Hz, 1H), 3.76 (s, 3H), 2.12 (s, 3H).  
 
13C-NMR (75 MHz, CDCl3): δ = 158.6 (Cq), 155.7 (Cq), 145.6 (CH), 143.66 (Cq), 136.8 (CH), 
135.7 (Cq), 128.7 (CH), 128.4 (CH), 127.4 (CH), 126.9 (CH), 116.2 (Cq), 113.8 (CH), 113.0 
(CH), 57.8 (CH), 55.2 (CH3), 17.1 (CH3). 
 
IR (neat): 3026, 1596, 1508, 1482, 1243, 1172, 1029, 697 cm-1. 
 
MS (EI) m/z (relative intensity): 304 ([M+], 43), 198 (18), 197 (100), 153 (22). 
 
HR-MS (EI) m/z calcd C20H20N2O+ 304.1576, found 304.1570. 
 









The representative procedure B was followed using N-benzyl-3-methylpyridin-2-amine (27a) 
(99 mg, 0.50 mmol) and 1-bromo-4-(tert-butyl)benzene (2k) (162 mg, 0.76 mmol). 
Purification by column chromatography on silica gel (n-hexane/EtOAc 99/1 → 98/2) yielded 
29ak (108 mg, 65%) as a colorless solid. 
 
M.p. = 121–123 °C. 
 
1H-NMR (300 MHz, CDCl3): δ = 7.96 (dd, J = 5.1, 1.7 Hz, 1H), 7.36–7.19 (m, 10H), 6.47–
6.54 (m, 2H), 4.67 (d, J = 7.1 Hz, 1H), 2.13 (s, 3H), 1.29 (s, 9H). 
 
13C-NMR (75 MHz, CDCl3): δ = 155.7 (Cq), 149.8 (Cq), 145.6 (CH), 143.6 (Cq), 140.4 (Cq), 
136.8 (CH), 128.4 (CH), 127.4 (CH), 127.3 (CH), 126.8 (CH), 125.4 (CH), 116.3 (Cq), 112.9 
(CH), 58.0 (CH), 34.4 (Cq), 31.3 (CH3), 17.1 (CH3). 
 
IR (neat): 3426, 2958, 1596, 1465, 785, 698 cm-1. 
 
MS (EI) m/z (relative intensity): 330 ([M+], 100), 238 (32), 223 (93), 193 (20). 
 
HR-MS (EI) m/z calcd C23H26N2+ 330.2096, found 330. 2100. 
 









The representative procedure B was followed using N-benzyl-3-methylpyridin-2-amine (27a) 
(99 mg, 0.50 mmol) and 1-bromo-4-chlorobenzene (2l) (143 mg, 0.75 mmol) at 150 °C. 
Purification by column chromatography on silica gel (n-hexane/EtOAc 99/1 → 98/2) yielded 
29al (82 mg, 53%) as a colorless solid. 
 
M.p: 116–118 °C. 
 
1H-NMR (300 MHz, CDCl3): δ = 7.94 (dd, J = 5.2, 1.8 Hz, 1H), 7.36–7.21 (m, 10H), 6.56–
6.43 (m, 2H), 4.58 (d, J = 6.7 Hz, 1H), 2.12 (s, 3H). 
 
13C-NMR (75 MHz, CDCl3): δ = 155.5 (Cq), 145.6 (CH), 143.0 (Cq), 141.1 (Cq), 136.1 (CH), 
132.6 (Cq), 128.8 (CH), 128.7 (CH), 128.5 (CH), 127.6 (CH), 127.3 (CH), 116.4 (Cq), 113.4 
(CH), 58.0 (CH), 17.0 (CH3). 
 
IR (neat): 3445, 2925, 1596, 1483, 1464, 1087, 755, 695 cm-1. 
 
MS (EI) m/z (relative intensity): 308 ([M+], 100), 216 (40), 201 (65), 166 (43), 165 (77). 
 
HR-MS (EI) m/z calcd for C19H17ClN2+ 308.1080, found 308. 1076. 
 









The representative procedure B was followed using N-benzyl-3-methylpyridin-2-amine (27a) 
(99 mg, 0.50 mmol) and 1-bromo-3-methylbenzene (2m) (135 mg, 0.78 mmol). Purification 
by column chromatography on silica gel (n-hexane/EtOAc 99/1 → 98/2) yielded 29am 
(91 mg, 63%) as a colorless oil. 
 
1H-NMR (300 MHz, CDCl3): δ = 7.97 (dd, J = 5.2, 1.7 Hz, 1H), 7.39–7.02 (m, 10H), 6.56–
6.48 (m, 2H), 4.65 (d, J = 7.0 Hz, 1H), 2.32 (s, 3H), 2.14 (s, 3H). 
 
13C-NMR (75 MHz, CDCl3): δ = 155.7 (Cq), 145.6 (CH), 143.5 (Cq), 143.4 (Cq), 138.1 (Cq), 
136.8 (CH), 128.4 (CH), 128.3 (CH), 127.8 (CH), 127.5 (CH), 127.5 (CH), 126.9 (CH), 124.5 
(CH), 116.2 (Cq), 112.9 (CH), 58.4 (CH), 21.5 (CH3), 17.1 (CH3). 
 
IR (neat): 3025, 1596, 1482, 1463, 1406, 773, 696 cm-1. 
 
MS (EI) m/z (relative intensity): 288 ([M+], 100), 287 (18), 196 (55), 181 (100), 165 (58). 
 
HR-MS (EI) m/z calcd for C20H20N2+ 288.1626, found 288. 1619. 
 









The representative procedure B was followed using N-benzyl-3-methylpyridin-2-amine (27a) 
(99 mg, 0.50 mmol) and 1-bromo-3-methoxybenzene (2n) (143 mg, 0.76 mmol). Purification 
by column chromatography on silica gel (n-hexane/EtOAc 99/1 → 98/2) yielded 29an 
(88 mg, 58%) as a colorless oil. 
 
1H-NMR (300 MHz, CDCl3): δ = 7.96 (dd, J = 5.1, 1.9 Hz, 1H), 7.36–7.18 (m, 7H), 6.94–6.86 
(m, 2H), 6.81–6.74 (m, 1H), 6.60–6.45 (m, 2H), 4.64 (d, J = 6.9 Hz, 1H), 3.75 (s, 3H), 2.13 
(s, 3H). 
 
13C-NMR (75 MHz, CDCl3): δ = 159.7 (Cq), 155.6 (Cq), 145.6 (CH), 145.1 (Cq), 143.3 (Cq), 
136.9 (CH), 129.5 (CH), 128.5 (CH), 127.5 (CH), 127.0 (CH), 119.9 (CH), 116.3 (Cq), 113.5 
(CH), 113.1 (CH), 112.0 (CH), 58.4 (CH), 55.1 (CH3), 17.0 (CH3). 
 
IR (neat): 2934, 1595, 1482, 1463, 1252, 1043, 773, 696 cm-1. 
 
MS (EI) m/z (relative intensity): 304 ([M+], 100), 303 (16), 212 (68), 197 (84). 
 
HR-MS (EI) m/z calcd for C20H20N2O+ 304.1576, found 304.1588. 
 









The representative procedure B was followed using N-benzyl-3-methylpyridin-2-amine (27a) 
(99 mg, 0.50 mmol) and 1-bromo-3,5-dimethylbenzene (2o) (142 mg, 0.76 mmol). 
Purification by column chromatography on silica gel (n-hexane/EtOAc 99/1 → 98/2) yielded 
29ao (96 mg, 63%) as a colorless solid. 
 
M.p: 117–119 °C. 
 
1H-NMR (300 MHz, CDCl3): δ = 7.96 (dd, J = 5.1, 1.7 Hz, 1H), 7.34–7.18 (m, 6H), 6.92 (s, 
2H), 6.87 (s, 1H), 6.54–6.42 (m, 2H), 4.63 (d, J = 7.1 Hz, 1H), 2.26 (s, 6H), 2.13 (s, 3H). 
 
13C-NMR (75 MHz, CDCl3): δ = 155.7 (Cq), 145.7 (CH), 143.6 (Cq), 143.4 (Cq), 137.9 (Cq), 
136.8 (CH), 128.8 (CH), 128.4 (CH), 127.4 (CH), 126.8 (CH), 125.4 (CH), 116.2 (Cq), 112.9 
(CH), 108.7 (Cq, J = 31.4 Hz), 58.4 (CH), 21.4 (CH3), 17.1 (CH3). 
 
IR (neat): 3446, 2918, 1596, 1465, 1404, 755, 698 cm-1. 
 
MS (EI) m/z (relative intensity): 302 ([M+] 100), 301 (14), 210 (35), 195 (75), 165 (35).  
 









The representative procedure B was followed using N-benzyl-3-methylpyridin-2-amine (27a) 
(99 mg, 0.50 mmol) and 4-bromo-1,2-dimethoxybenzene (2p) (173 mg, 0.79 mmol). 
Purification by column chromatography on silica gel (n-hexane/EtOAc 99/1 → 98/2) yielded 
29ap (91 mg, 55%) as a light brown solid. 
 
M.p: 134–136 °C. 
 
1H-NMR (300 MHz, CDCl3): δ = 7.95 (dd, J = 5.2, 1.8 Hz, 1H), 7.37–7.15 (m, 6H), 6.87–6.74 
(m, 3H), 6.55–6.41 (m, 2H), 4.59 (d, J = 7.0 Hz, 1H), 3.82 (s, 3H), 3.78 (s, 3H), 2.11 (s, 3H). 
 
13C-NMR (75 MHz, CDCl3): δ = 155.7 (Cq), 148.9 (Cq), 148.0 (Cq), 145.6 (CH), 143.5 (Cq), 
136.9 (CH), 136.1 (Cq), 128.4 (CH), 127.4 (CH), 126.9 (CH), 119.5 (CH), 116.2 (Cq), 113.1 
(CH), 111.2 (CH), 111.0 (CH), 58.1 (CH), 55.8 (CH3), 55.8 (CH3), 17.1 (CH3). 
 
IR (neat): 3398, 3005, 2934, 1595, 1512, 1269, 1137, 1021, 701 cm-1. 
 
MS (EI) m/z (relative intensity): 334 ([M+], 52), 228(16), 227 (100). 
 









The representative procedure B was followed using N-benzyl-3-methylpyridin-2-amine (27a) 
(99 mg, 0.50 mmol) and 5-bromo-1,2,3-trimethoxybenzene (2e) (185 mg, 0.75 mmol). 
Purification by column chromatography on silica gel (n-hexane/EtOAc 99/1 → 95/5 → 90/10) 
yielded 29ae (97 mg, 54%) as a violet solid. 
 
M.p: 174–176 °C. 
 
1H-NMR (300 MHz, CDCl3): δ = 7.96 (dd, J = 5.1, 1.7 Hz, 1H), 7.34–7.19 (m, 6H), 6.55–6.49 
(m, 3H), 6.44 (d, J = 6.9 Hz, 1H), 4.60 (d, J = 6.9 Hz, 1H), 3.81 (s, 3H), 3.75 (s, 6H), 2.13 (s, 
3H). 
 
13C-NMR (125 MHz, CDCl3): δ = 155.6 (Cq), 153.1 (Cq), 145.5 (CH), 143.2 (Cq), 139.0 (Cq), 
136.9 (CH), 136.8 (Cq), 128.4 (CH), 127.3 (CH), 126.9 (CH), 116.2 (Cq), 113.1 (CH), 104.7 
(CH), 60.7 (CH3), 58.5 (CH), 55.9 (CH3), 16.9 (CH3). 
 
IR (neat):.3399, 2970, 1589, 1487, 1460, 1157, 1008 cm-1. 
 
MS (EI) m/z (relative intensity): 364 ([M+], 58), 349 (15), 258 (15), 257 (100). 
 









The representative procedure B was followed using N-benzyl-3-methylpyridin-2-amine (27a) 
(99 mg, 0.50 mmol) and 5-bromo-1H-indole (2q) (147 mg, 0.75 mmol). Purification by 
column chromatography on silica gel (n-pentane/EtOAc 5/1 → 2/1) yielded 29aq (102 mg, 
65%) as a colorless solid. 
 
M.p: 148–149 °C. 
 
1H-NMR (300 MHz, CDCl3): δ = 8.57 (sbr, 1H), 7.98 (dd, J = 5.1, 1.7 Hz, 1H), 7.60–7.54 (m, 
1H), 7.42–7.35 (m, 2H), 7.32–7.20 (m, 5H), 7.16–7.04 (m, 2H), 6.63 (d, J = 6.7 Hz, 1H), 6.52 
(dd, J = 7.1, 5.1 Hz, 1H), 6.56–6.45 (m, 1H), 4.78 (d, J = 6.7 Hz, 1H), 2.15 (s, 3H). 
 
13C-NMR (125 MHz, CDCl3): δ = 155.8 (Cq), 145.5 (CH), 144.0 (Cq), 136.8 (CH), 135.0 (Cq), 
134.9 (Cq), 128.2 (CH), 127.8 (Cq), 127.4 (CH), 126.6 (CH), 124.8 (CH), 122.1 (CH), 119.4 
(CH), 116.3 (Cq), 112.8 (CH), 111.3 (CH), 102.4 (CH), 58.9 (CH), 17.1 (CH3). 
 
IR (neat): 3641, 3024, 1599, 1467, 1427, 1277, 1107, 896, 799, 772, 723, 696 cm-1. 
 
MS (EI) m/z (relative intensity): 313 ([M+], 85), 221 (45), 207 (45), 206 (100), 204 (55), 179 
(40), 178 (30), 92 (25), 65 (10). 
 






H/D Exchange in substrate 27a with D2O as the co-solvent 
 
 
N-Benzyl-3-methylpyridin-2-amine (1a) (99 mg, 0.50 mmol, 1.0 equiv), [Ru(O2CMes)2(p-
cymene)] (16) (14 mg, 0.025 mmol, 5.0 mol %) and Na2CO3 (159 mg, 1.50 mmol, 3.0 equiv) 
were placed in a 25 mL sealed tube with a septum screw cap under an inert atmosphere of 
nitrogen. After adding 1.8 mL o-xylene and 0.2 mL D2O, the septum screw cap was removed 
and a teflon lined cap was fixed immediately. The reaction mixture was stirred at 140 °C for 
24 h. At ambient temperature, the suspension was filtered through a short pad of Celite®, 
which was further washed with CH2Cl2 (50 mL). Evaporation of the solvent in vacuo and 
purification by column chromatography on silica gel (n-hexane/EtOAc 99/1 → 98/2) yielded 
[Dn]-27a) as a colorless oil (85 mg, 86%, 65%-D), as estimated by 1H-NMR. 
 
1H NMR (300 MHz, CDCl3): δ = 8.04 (dd, J = 5.1, 1.7 Hz, 1H), 7.43–7.19 (m, 6H), 6.55 
(dd, J = 7.1, 5.1 Hz, 1H), 4.68 (d, J = 5.4 Hz, 2H), 4.35 (sbr, 1H), 2.07 (s, 3H). 
 
13C NMR (125 MHz, CDCl3): δ = 156.6 (Cq), 145.4 (CH), 140.0 (Cq), 136.8 (CH), 128.5 (CH), 
127.8 (CH), 127.1 (CH), 116.4 (Cq), 112.9 (CH), 45.8 (CH2), 45.5 (CHD, J = 21.0 Hz), 17.0 
(CH3). 
 
IR (neat): 3447, 3027, 1597, 1490, 1466, 1381, 696 cm–1 
 
MS (EI) m/z(relative intensity): 200 (23), 199 (77), 198 (100), 197 (33), 108 (27), 107 (80), 
106 (77), 93 (47), 92 (65), 91 (38), 65 (38). 
 
HRMS (ESI) m/z calcd for [C13H12D2N2 + H]+ 201.1355, found 201.1355 
m/z calcd for [C13H13DN2 + H]+ 200.1293, found 200.1292,  












5.5 Hydroarylation of alkynes 




(E)-[1-(3-Methoxyphenyl)-1,2-diphenyl] ethene (72aa) 
 
The general procedure C was followed using 2-methoxy benzoic acid (48a) (152 mg, 
1.00 mmol) and diphenylacetylene (34a) (89 mg, 0.50 mmol) in DCE (2.0 mL). Purification 
by column chromatography (nhexane/EtOAc: 99/1) yielded 72aa (140 mg, 98%) as light 
yellow oil. 
 
1H NMR (500 MHz, CDCl3): δ = 7.35–7.30 (m, 3H), 7.25–7.19 (m, 3H), 7.15–7.10 (m, 3H), 
7.04–7.01 (m, 2H), 6.98 (s, 1H), 6.92 (ddd, J = 7.7, 1.7, 0.9 Hz, 1H), 6.88 (dd, J = 2.5, 
1.7 Hz, 1H), 6.84 (ddd, J = 8.2, 2.6, 0.9 Hz, 1H), 3.78 (s, 3H). 
 
13C NMR (126 MHz, CDCl3): δ = 160.0 (Cq), 145.1 (Cq), 142.6 (Cq), 140.4 (Cq), 137.4 (Cq), 
130.5 (CH), 129.7 (CH), 129.2 (CH), 128.7 (CH), 128.5 (CH), 128.1 (CH), 127.6 (CH), 126.9 
(CH), 120.4 (CH), 113.6 (CH), 113.0 (CH), 55.4 (CH3). 
 
IR (ATR): 3020, 2832, 1593, 1576, 1483, 1260, 1074, 1000, 754, 691 cm–1. 
 
MS (EI) m/z (relative intensity): 286 (100) [M+], 255 (15), 253 (22), 252 (14), 178 (14), 165 
(14). 
 
HR-MS (EI) m/z calcd for C21H18O, [M+] 286.1358, found 286.1360. 
 








(E)-[1-(3-Ethoxyphenyl)-1,2-diphenyl] ethene (72ba) 
 
The general procedure C was followed using 2-ethoxy benzoic acid (48b) (166 mg, 
1.00 mmol) and diphenylacetylene (34a) (89 mg, 0.50 mmol) in PhMe (2.0 mL). Purification 
by column chromatography (nhexane) yielded 72ba (131 mg, 87%) as a colourless oil. 
 
1H NMR (500 MHz, CDCl3): δ = 7.27–7.22 (m, 3H), 7.18–7.11 (m, 3H), 7.07–7.01 (m, 3H), 
6.95–6.93 (m, 2H), 6.89 (s, 1H), 6.83 (ddd, J = 7.7, 1.7, 0.9 Hz, 1H), 6.80–6.79 (m, 1H), 6.75 
(ddd, J = 8.2, 2.6, 0.9 Hz, 1H), 3.93 (q, J = 7.0 Hz, 2H), 1.31 (t, J = 7.0 Hz, 3H). 
 
13C NMR (126 MHz, CDCl3): δ = 159.0 (Cq), 145.1 (Cq), 142.6 (Cq), 140.4 (Cq), 137.5 (Cq), 
130.5 (CH), 129.7 (CH), 129.2 (CH), 128.7 (CH), 128.4 (CH), 128.1 (CH), 127.5 (CH), 126.9 
(CH), 120.3 (CH), 114.2 (CH), 113.5 (CH), 63.5 (CH2), 15.0 (CH3). 
 
IR (ATR): 3022, 2977, 1594, 1574, 1441, 1262, 1200, 1048, 772, 691 cm–1. 
 
MS (EI) m/z (relative intensity) 300 (100) [M+], 271 (22), 253 (18), 252 (15), 239 (12), 165 
(15). 
 







(E)-[1-(3-Pheoxyphenyl)-1,2-diphenyl] ethene (72ca) 
 
The general procedure C was followed using 2-phenoxy benzoic acid (48c) (214 mg, 
1.00 mmol) and diphenylacetylene (34a) (89 mg, 0.50 mmol) in PhMe (2.0 mL). Purification 
by column chromatography (nhexane) yielded 72ca (105 mg, 60%) as a yellow oil. 
 
1H NMR (500 MHz, CDCl3): δ = 7.35–7.30 (m, 5H), 7.27–7.20 (m, 3H), 7.15–7.09 (m, 3H), 
7.09–7.03 (m, 3H), 7.03–7.00 (m, 4H), 6.97 (s, 1H), 6.91 (ddd, J = 8.1, 2.4, 1.0 Hz, 1H). 
 
13C NMR (126 MHz, CDCl3): δ = 157.4 (Cq), 157.2 (Cq), 145.5 (Cq), 142.1 (Cq), 140.1 (Cq), 
137.3 (Cq), 130.5 (CH), 129.8 (CH), 129.7 (CH), 129.5 (CH), 128.8 (CH), 128.7 (CH), 128.1 
(CH), 127.7 (CH), 127.0 (CH), 123.3 (CH), 122.9 (CH), 118.8 (CH), 118.4 (CH), 118.0 (CH). 
 
IR (ATR): 3055, 3022, 1589, 1573, 1487, 1478, 1261, 1217, 776, 689 cm–1. 
 
MS (EI) m/z (relative intensity) 348 (100) [M+], 255 (33), 253 (28), 252 (18), 213 (15), 178 
(18), 77 (18), 51 (12). 
 









1,1,2- Triphenylethylene (72da) 
 
The general procedure C was followed using benzoic acid (48d) (122 mg, 1.00 mmol) and 
diphenylacetylene (34a) (89 mg, 0.50 mmol) in PhMe (2.0 mL). Purification by column 
chromatography (nhexane) yielded 72da (55 mg, 43%) as a colourless solid. 
 
M.p: 71-73 °C. 
 
1H NMR (500 MHz, CDCl3): δ = 7.35–7.27 (m, 8H), 7.22–7.20 (m, 2H), 7.15–7.09 (m, 3H), 
7.04–7.02 (m, 2H), 6.97 (s, 1H). 
 
13C NMR (126 MHz, CDCl3): δ = 143.6 (Cq), 142.7 (Cq), 140.5 (Cq), 137.5 (Cq), 130.5 (CH), 
129.7 (CH), 128.8 (CH), 128.3 (CH), 128.3 (CH), 128.1 (CH), 127.7 (CH), 127.6 (CH), 127.5 
(CH), 126.9 (CH). 
 
IR (ATR): 3077, 3054, 3021, 1575, 1490, 775, 722, 690, 586 cm–1. 
 
MS (EI) m/z (relative intensity) 256 (100) [M+], 255 (22), 179 (25), 178 (37), 43 (18). 
 
HR-MS (EI) m/z calcd for C20H16, [M+] 256.1252, found 256.1254. 
 








(E)-[1-(3-Fluorophenyl)-1,2-diphenyl] ethene (72ea) 
 
The general procedure C was followed using 2-fluorobenzoic acid (48e) (140 mg, 
1.00 mmol), diphenylacetylene (34a) (89 mg, 0.50 mmol) in DCE (2.0 mL). Purification by 
column chromatography (nhexane) yielded 72ea (108 mg, 79%) as colourless solid. 
 
M.p: 67-69 °C. 
 
1H NMR (600 MHz, CDCl3): δ = 7.35–7.32 (m, 3H), 7.28–7.24 (m, 1H), 7.20–7.18 (m, 2H), 
7.15–7.09 (m, 4H), 7.03–6.99 (m, 3H), 6.98 (s, 1H), 6.97–6.94 (m, 1H). 
 
13C NMR (126 MHz, CDCl3): δ = 163.0 (Cq, 1JC-F = 245.2 Hz), 145.9 (Cq, 3JC-F = 7.3 Hz), 
141.6 (Cq,4JC-F = 2.4 Hz), 139.9 (Cq), 137.0 (Cq), 130.4 (CH), 129.8 (CH), 129.7 (CH, 3JC-
F = 8.4 Hz), 129.2 (CH), 128.9 (CH), 128.2 (CH), 127.8 (CH), 127.2 (CH), 123.3 (CH, 4JC-
F = 2.6 Hz), 114.6 (CH, 2JC-F = 20.4 Hz), 114.4 (CH, 2JC-F = 19.7 Hz). 
 
19F{1H} NMR (300 MHz, CDCl3): δ = -114.7 (s). 
 
IR (ATR): 3055, 3020, 1574, 1524, 1492, 1478, 1184, 1157, 872, 691 cm–1. 
 
MS (EI) m/z (relative intensity) 274 (100) [M+], 273 (22), 259 (20), 196 (22), 178 (18), 43 
(35). 
 








(E)-[1-(3-Chlorophenyl)-1,2-diphenyl] ethene (72fa) 
 
The general procedure C was followed using 2-chloro benzoic acid (48f) (157 mg, 
1.00 mmol) and diphenylacetylene (34a) (89 mg, 0.50 mmol) in PhMe (2.0 mL). Purification 
by column chromatography (nhexane) yielded 72fa (77 mg, 53%) as a yellow oil. 
 
1H NMR (600 MHz, CDCl3): δ = 7.37–7.36 (m, 3H), 7.34–7.36 (m, 1H), 7.29–7.26 (m, 2H), 
7.26–7.22 (m, 1H), 7.22–7.19 (m, 2H), 7.17–7.13 (m, 3H), 7.06–7.03 (m, 2H), 7.02 (s, 1H). 
 
13C NMR (126 MHz, CD2Cl2): δ = 145.7 (Cq), 141.6 (Cq), 140.1 (Cq), 137.3 (Cq), 134.4 (Cq), 
130.5 (CH), 129.9 (CH), 129.8 (CH), 129.5 (CH), 129.1 (CH), 128.3 (CH), 128.0 (CH), 127.8 
(CH), 127.7 (CH), 127.4 (CH), 126.1 (CH). 
 
IR (ATR): 3055, 3021, 1618, 1588, 1561, 1491, 1471, 1444, 741, 653 cm–1. 
 
MS (EI) m/z (relative intensity) 290 (100) [M+], 253 (37), 252 (30), 239 (18), 179 (22), 178 
(33), 176 (15), 126 (12). 
 








(E)-[1-(3-Nitrophenyl)-1,2-diphenyl] ethene (72ga) 
 
The general procedure C was followed using 2-nitrobenzoic acid (48g) (167 mg, 1.00 mmol) 
and diphenylacetylene (34a) (89 mg, 0.50 mmol) in PhMe (2.0 mL). Purification by column 
chromatography (nhexane/EtOAc: 97/3) yielded 72ga (66 mg, 44%) as yellow solid. 
 
M.p: 148-150 °C. 
 
1H NMR (600 MHz, CD2Cl2): δ = 8.19 (dd, J = 2.1, 2.1 Hz, 1H), 8.13–8.11 (m, 1H), 7.67–7.63 
(m, 1H), 7.49 (dd, J = 8.0, 8.0 Hz, 1H), 7.42–7.38 (m, 3H), 7.23–7.20 (m, 2H), 7.17–7.15 (m, 
3H), 7.11 (s, 1H), 7.09–7.06 (m, 2H). 
 
13C NMR (126 MHz, CD2Cl2): δ = 148.7 (Cq), 145.4 (Cq), 140.7 (Cq), 139.5 (Cq), 137.0 (Cq), 
133.7 (CH), 130.7 (CH), 130.5 (CH), 130.0 (CH), 129.4 (CH), 129.1 (CH), 128.3 (CH), 128.3 
(CH), 127.7 (CH), 122.4 (CH), 122.3 (CH). 
 
IR (ATR): 3034, 3014, 1571, 1493, 1444, 1346, 860, 780, 740, 695 cm–1. 
 
MS (EI) m/z (relative intensity) 301 (100) [M+], 253 (35), 252 (30), 239 (22), 179 (20). 
 








(E)-{1-(3-Ethoxyphenyl)-1,2-bis-[p-tolyl]} ethene (72bb) 
 
The general procedure C was followed using 2-ethoxy benzoic acid (48b) (166 mg, 
1.00 mmol), di(4-methylphenyl)acetylene (34b) (103 mg, 0.50 mmol) in PhMe (2.0 mL). 
Purification by column chromatography using (nhexane/EtOAc: 99/1) yielded 72bb (126 mg, 
76%) as a yellow oil. 
 
1H NMR (500 MHz, CDCl3): δ = 7.21 (dd, J = 7.9, 7.9 Hz, 1H), 7.17–7.07 (m, 4H), 6.98–6.84 
(m, 7H), 6.80 (ddd, J = 8.2, 2.5, 0.9 Hz, 1H), 4.00 (q, J = 7.0 Hz, 2H), 2.38 (s, 3H), 2.26 (s, 
3H), 1.38 (t, J = 7.0 Hz, 3H). 
 
13C NMR (75 MHz, CDCl3): δ = 158.9 (Cq), 145.5 (Cq), 141.7 (Cq), 137.5 (Cq), 137.1(Cq), 
136.6 (Cq), 134.8 (Cq), 130.3 (CH), 129.6 (CH), 129.5 (CH), 129.1(CH), 128.8 (CH), 128.1 
(CH), 120.3 (CH), 114.2 (CH), 113.3 (CH), 63.5 (CH2), 21.5 (CH3), 21.3 (CH3), 15.0 (CH3). 
 
IR (ATR): 3021, 2977, 1593, 1574, 1262, 1198, 1050, 776, 729, 697 cm–1. 
 
MS (EI) m/z (relative intensity) 328 (100) [M+], 285 (18), 252 (10). 
 








(E)-[1-(3-Ethoxyphenyl)-1,2-bis-(p-anisyl)] ethene (72bc) 
 
The general procedure C was followed using 2-ethoxy benzoic acid (48b) (166 mg, 
1.00 mmol), 1,2-bis(4-methoxyphenyl)ethyne (34c) (119 mg, 0.50 mmol) in PhMe (2.0 mL). 
Purification by column chromatography (nhexane/EtOAc: 49/1) yielded 72bc (152 mg, 84%) 
as a colourless oil. 
 
1H NMR (400 MHz, CDCl3): δ = 7.14–7.09 (m, 1H), 7.06–7.02 (m, 2H), 6.93–6.88 (m, 2H), 
6.83–6.77 (m, 5H), 6.72 (ddd, J = 8.1, 2.6, 0.9 Hz, 1H), 6.63–6.56 (m, 2H), 3.92 (q, 
J = 7.0 Hz, 2H), 3.76 (s, 3H), 3.67 (s, 3H), 1.31 (t, J = 7.0 Hz, 3H). 
 
13C NMR (75 MHz, CDCl3): δ = 159.0 (Cq), 159.0 (Cq), 158.4 (Cq), 145.6 (Cq), 140.3 (Cq), 
132.9 (Cq), 131.7 (CH), 130.9 (CH), 130.4 (Cq), 129.1 (CH), 127.6 (CH), 120.2 (CH), 114.2 
(CH), 114.1 (CH), 113.6 (CH), 113.2 (CH), 63.5 (CH2), 55.3 (CH3), 55.3 (CH3), 15.0 (CH3). 
 
IR (ATR): 2977, 2834, 1600, 1573, 1506, 1284, 1241, 1172, 1030, 826, 789 cm–1. 
 
MS (EI) m/z (relative intensity) 360 (100) [M+], 345 (10), 209 (10), 181 (8). 
 








(E)-[1-(3-Benzyloxyphenyl)-1,2-diphenyl] ethene (72ia) 
 
The general procedure C was followed using 4-benzyloxy benzoic acid (48i) (228 mg, 
1.00 mmol) and diphenylacetylene (34a) (89 mg, 0.50 mmol) in DCE (2.0 mL). Purification 
by column chromatography (nhexane/EtOAc: 99/1) yielded 72ia (100 mg, 55%) as a 
colourless oil. 
 
1H NMR (600 MHz, CD2Cl2): δ = 7.43–7.32 (m, 8H), 7.25–7.23 (m, 1H), 7.22–7.19 (m, 2H), 
7.15–7.09 (m, 3H), 7.05–7.03 (m, 2H), 7.02 (s, 1H), 6.96–6.94 (m, 2H), 6.93–6.90 (m, 1H), 
5.04 (s, 2H). 
 
13C NMR (76 MHz, CD2Cl2): δ = 159.1 (Cq), 145.3 (Cq), 142.8 (Cq), 140.7 (Cq), 137.8 (Cq), 
137.5 (Cq), 130.7 (CH), 129.9 (CH), 129.5 (CH), 129.0 (CH), 128.9 (CH), 128.7 (CH), 128.3 
(CH), 128.3 (CH), 128.0 (CH), 127.8 (CH), 127.2 (CH), 120.7 (CH), 114.7 (CH), 114.1 (CH), 
70.3 (CH2). 
 
IR (ATR): 3055, 3022, 1589, 1573, 1183, 1128, 873, 719, 689 cm–1. 
 
MS (EI) m/z (relative intensity) 362 (53) [M+], 271 (15), 91 (100). 
 








(E)-[1-(m-Tolyl)-1,2-diphenyl] ethene (72ha) 
 
The general procedure C was followed using 4-methylbenzoic acid (48h) (136 mg, 
1.00 mmol) and diphenylacetylene (34a) (89 mg, 0.50 mmol) in PhMe (2.0 mL). Purification 
by column chromatography (nhexane) yielded 72ha (80 mg, 59%) as a colourless oil. 
 
1H NMR (600 MHz, CD2Cl2): δ = 7.41–7.37 (m, 3H), 7.26–7.22 (m, 4H), 7.19–7.13 (m, 5H), 
7.10–7.07 (m, 2H), 7.03 (s, 1H), 2.37 (s, 3H). 
 
13C NMR (126 MHz, CD2Cl2): δ = 143.7 (Cq), 143.1 (Cq), 140.9 (Cq), 138.2 (Cq), 137.9 (Cq), 
130.6 (CH), 129.9 (CH), 128.9 (CH), 128.6 (CH), 128.5 (CH), 128.4 (CH), 128.3 (CH), 128.2 
(CH), 127.7 (CH), 127.0 (CH), 125.1 (CH), 21.7 (CH3). 
 
IR (ATR): 3053, 3020, 1599, 1491, 1444, 781, 754, 717, 690, 595 cm–1. 
 
MS (EI) m/z (relative intensity) 270 (100) [M+], 255 (38), 253 (18), 239 (12), 178 (28), 43 
(21). 
HR-MS (EI) m/z calcd for C21H18, [M+] 270.1409, found 270.1411. 
 








(E)-[1-(3-Hydroxyphenyl)-1,2-diphenyl] ethene (72ja) 
The general procedure C was followed using salicylic acid (48j) (138 mg, 1.00 mmol) and 
diphenylacetylene (34a) (89 mg, 0.50 mmol) in PhMe (2.0 mL). Purification by column 
chromatography (nhexane/EtOAc: 97/3) yielded 72ja (87 mg, 64%) as a beige solid. 
 
M.p: 126-128 °C. 
 
1H NMR (500 MHz, CDCl3): δ = 7.34–7.30 (m, 3H), 7.21–7.16 (m, 3H), 7.14–7.09 (m, 3H), 
7.02–6.99 (m, 2H), 6.96 (s, 1H), 6.95–6.92 (m, 1H), 6.77–6.72 (m, 2H), 4.70 (s, 1H). 
 
13C NMR (126 MHz, CDCl3): δ = 155.4 (Cq), 145.3 (Cq), 142.2 (Cq), 140.3 (Cq), 137.3 (Cq), 
130.5 (CH), 129.7 (CH), 129.5 (CH), 128.8 (CH), 128.5 (CH), 128.1 (CH), 127.6 (CH), 127.0 
(CH), 120.4 (CH), 114.7 (CH), 114.6 (CH). 
 
IR (ATR): 3250 (br), 3017, 1578, 1492, 1443, 1269, 1191, 753, 718, 690 cm–1. 
 
MS (EI) m/z (relative intensity) 272 [M+], 58 (18), 44 (21), 43 (100). 
 








(E)-5-Bromo-2-(1,2-diphenylvinyl)benzoic acid (72ka) 
The general procedure C was followed using 3-bromo benzoic acid (48k) (201 mg, 
1.00 mmol) and diphenylacetylene (34a) (89 mg, 0.50 mmol) in DCE (2.0 mL). Purification 
by column chromatography (nhexane/EtOAc: 5/1) yielded 72ka' (27 mg, 14%) as colorless 
solid and 72ka as colorless viscous liquid (43 mg, 26%). 
 
M.p: 190-192 °C. 
 
1H NMR (400 MHz, CDCl3): δ = 7.92 (d, J = 2.2 Hz, 1H), 7.60 (dd, J = 8.2, 2.2 Hz, 2H), 7.22 
(d, J = 8.2 Hz, 1H), 7.16–7.07 (m, 10H), 6.58 (s, 1H). 
 
13C NMR (101 MHz, CDCl3): δ = 170.8 (Cq), 144.6 (Cq), 141.1 (Cq), 139.4 (Cq), 137.2 (Cq), 
134.8 (CH), 133.1 (CH), 132.9 (CH), 132.0 (Cq), 130.6 (CH), 130.3 (CH), 129.5 (CH), 128.2 
(CH), 127.6 (CH), 127.3 (CH), 121.2 (Cq). 
 
IR (ATR): 1703, 1675, 1440, 1292, 1096, 1072, 775, 759, 696 cm–1. 
 
MS (EI) m/z (relative intensity) 378 (100) [M+], 361 (21), 334 (11), 252 (100), 165 (16), 105 
(50), 77 (40). 
 







(E)-[1-(4-Bromophenyl)-1,2-diphenyl] ethene (72ka') 
1H NMR (600 MHz, CDCl3): δ = 7.45–7.42 (m, 2H), 7.34 (dd, J = 5.0, 1.9 Hz, 3H), 7.22–7.17 
(m, 4H), 7.16 – 7.11 (m, 3H), 7.03 (dd, J = 7.7, 1.9 Hz, 2H), 6.96 (s, 1H). 
 
13C NMR (76 MHz, CDCl3): δ = 142.5 (Cq), 141.6 (Cq), 140.0 (Cq), 137.2 (Cq), 131.4 (CH), 
130.4 (CH), 129.7 (CH), 129.3 (CH), 128.9 (CH), 128.7 (CH), 128.1 (CH), 127.8 (CH), 127.1 
(CH), 121.7 (Cq). 
 
IR (ATR): 3021, 1487, 1443, 1072, 1007, 834, 728, 694, cm–1. 
 
MS (EI) m/z (relative intensity) 334 (100) [M+], 253 (17), 252 (13), 239 (9), 178 (16). 
 





5.6 Ruthenium(II)-catalyzed C(sp2)–H borylations 





The general procedure D was followed using benzo[h]quinoline (1a) (179 mg, 1.00 mmol) 
and B2pin2 (62a) (254 mg, 1.00 mmol) in 1,4-dioxane (2.5 mL). After 20 h, purification by 
Kuglerohr distillation yielded 70aa (228 mg, 75%) as a colorless solid. 
 
M.p.: 167-169 °C 
 
1H NMR (400 MHz, CDCl3): δ = 8.90 (dd, J = 4.5, 1.6 Hz, 1H), 8.18 (dd, J = 8.0, 1.6 Hz, 1H), 
7.88 (dd, J = 7.8, 1.3 Hz, 1H), 7.82–7.75 (m, 2H), 7.72–7.64 (m, 2H), 7.52 (dd, J = 8.0, 
4.5 Hz, 1H), 1.55 (s, 12H) 
 
13C NMR (101 MHz, CDCl3): δ = 146.8 (Cq), 146.5 (CH), 136.1 (CH), 134.5 (Cq), 132.7 (Cq), 
130.9 (CH), 128.3 (CH), 128.2 (CH), 128.0 (CH), 126.4 (Cq), 124.6 (CH), 121.8 (CH), 83.4 
(Cq), 25.4 (CH3). 
 
11B NMR (128 MHz, CDCl3): δ = 30.8 
 
IR (neat): ṽ = 2976, 1511, 1368, 1341, 1314, 1132, 1101, 969, 852, 825 cm−1. 
 
HR-MS (ESI): m/z calcd for C19H21BNO2+ [M+H+] 306.1660, found 306.1663. 
 
Note: A resonance for the carbon directly attached to the boron atom was not observed. 
 











The general procedure D was followed using benzo[h]quinoline (1a) (45 mg, 0.25 mmol) and 
B2cat2 (62b) (59 mg, 0.25 mmol) in 1,4-dioxane (1.0 mL). After 20 h, purification by 
Kugelrohr distillation yielded 70ab (72 mg, 97%) as a violet solid. 
 
M.p.: 190-192 °C. 
 
1H NMR (400 MHz, CDCl3): δ = 8.47–8.42 (m, 2H), 8.00–7.96 (m, 2H), 7.90 (dd, J = 8.0, 
1.0 Hz, 1H), 7.84 (dd, J = 8.0, 6.7 Hz, 1H), 7.73 (d, J = 9.0 Hz, 1H), 7.56 (dd, J = 8.0, 5.2 Hz, 
1H), 7.01 (dd, J = 5.7, 3.3 Hz, 2H), 6.88 (dd, J = 5.7, 3.3 Hz, 2H). 
 
13C NMR (101 MHz, CDCl3): δ = 152.0 (Cq), 145.6 (Cq), 141.3 (CH), 139.8 (CH), 134.5 (Cq), 
132.0 (CH), 130.7 (Cq), 130.5 (CH), 129.5 (CH), 125.9 (CH), 124.8 (Cq), 122.6 (CH), 122.3 
(CH), 119.9 (CH), 110.7 (CH). 
 
11B NMR (128 MHz, CDCl3): δ = 16.6. 
 
IR (neat): ṽ = 3032, 1476, 1462, 1228, 1213, 1168, 1065, 743, 719 cm−1. 
 
MS (EI) m/z (relative intensity) 297 (100) [M+], 253 (15), 207 (15), 191 (35), 164 (50), 91 
(75), 84 (25), 77 (20), 65 (15), 43 (35). 
 
HR-MS (EI) m/z calcd for C19H12BNO2, [M+] 297.0961, found 297.0959. 
 









The general procedure D was followed using 2-(1H-pyrrol-1-yl)pyridine (1b) (36 mg, 
0.25 mmol) and B2pin2  (62a) (63 mg, 0.25 mmol) in 1,4-dioxane (1.0 mL). After 20 h, 
purification by flash column chromatography on silica gel (EtOAc/NEt3: 98/2) and HPLC 
yielded 70ba (42 mg, 42%) as a red viscous liquid. 
 
1H NMR (600 MHz, CDCl3): δ = 8.38–8.36 (m, 1H), 8.34–8.32 (m, 1H), 7.87 (ddd, J = 8.8, 
7.3, 1.7 Hz, 1H), 7.16–7.13 (m, 1H), 6.76 (s, 2H), 1.30 (s, 24H). 
 
13C NMR (126 MHz, CDCl3): δ = 152.1 (Cq), 143.0 (CH), 141.8 (CH), 123.5 (CH), 119.5 
(CH), 114.5 (CH), 82.4 (Cq), 25.4 (CH3). 
 
11B NMR (128 MHz, CDCl3): δ = 20.8. 
 
IR (neat): ṽ = 2973, 1590, 1474, 1455, 1340, 1134, 925, 966, 675 cm−1. 
 
HR-MS (ESI): m/z calcd for C21H31B2N2O4+ [M+H+] 397.2464, found 397.2472. 
 











The general procedure D was followed using 1-(o-tolyl)-1H-pyrazole (1c) (40 mg, 0.25 mmol) 
and B2pin2 (62a) (63 mg, 0.25 mmol) in 1,4-dioxane (1.0 mL). After 20 h, purification by flash 
column chromatography on silica gel (EtOAc/NEt3: 98/2) and HPLC yielded 70ca (45 mg, 
63%) as a light yellow oil. 
 
1H NMR (400 MHz, CDCl3): δ =7.66 (dd, J = 1.9, 0.6 Hz, 1H), 7.59–7.56 (m, 2H), 7.35–7.29 
(m, 2H), 6.38 (t, J = 2.1 Hz, 1H), 2.11 (s, 3H), 1.19 (s, 12H). 
 
13C NMR (126 MHz, CDCl3): δ = 143.7 (Cq), 138.9 (CH), 133.5 (Cq), 132.8 (CH), 132.3 (CH), 
130.9 (CH), 128.2 (CH), 105.8 (CH), 83.5 (Cq), 25.0 (CH3), 18.0 (CH3). 
 
11B NMR (128 MHz, CDCl3): δ = 28.6. 
 
IR (neat): ṽ = 2977, 1590, 1460, 1354, 1138, 1112, 1080, 851, 746 cm−1. 
 
HR-MS (ESI): m/z calcd for C16H22BN2O2+ [M+H+] 285.1769, found 285.1772. 
 











The general procedure D was followed using 2-phenylpyridine (1d) (78 mg, 0.50 mmol) and 
B2pin2 (62a) (127 mg, 0.50 mmol) in 1,4-dioxane (2.0 mL). After 20 h, purification by flash 
column chromatography on silica gel (EtOAc/NEt3: 99/1) and HPLC yielded 70da (80 mg, 
57%) was obtained as a white solid. 
 
M.p.: 129-131 °C 
 
1H NMR (400 MHz, CDCl3): δ = 8.65 (ddd, J = 5.6, 1.5, 0.9 Hz, 1H), 7.93 (ddd, J = 8.0, 7.4, 
1.5 Hz, 1H), 7.78 (dt, J = 8.0, 1.1 Hz, 1H), 7.72 (dt, J = 7.2, 1.0 Hz, 1H), 7.64 (dt, J = 7.6, 
0.9 Hz, 1H), 7.40 (td, J = 7.3, 1.1 Hz, 1H), 7.34 (ddd, J = 7.4, 5.6, 1.2 Hz, 1H), 7.27 (dd, 
J = 7.5, 1.2 Hz, 1H), 1.42 (s, 12H). 
 
13C NMR (101 MHz, CDCl3): δ = 156.6 (Cq), 143.3 (CH), 141.9 (CH), 137.2 (Cq), 131.5 (CH), 
131.5 (CH), 127.9 (CH), 122.8 (CH), 121.3 (CH), 117.5 (CH), 80.3 (Cq), 27.1 (CH3). 
 
11B NMR (128 MHz, CDCl3): δ = 13.7. 
 
IR (neat): ṽ = 2974, 1519, 1359, 1318, 1138, 1128, 950, 859 cm−1. 
 
HR-MS (ESI): m/z calcd for C17H20BNNaO2+ [M+Na+] 304.1479, found 304.1482. 
 
Note: A resonance for the carbon directly attached to the boron atom was not observed. 
 










The general procedure D was followed using 2-(4-methoxyphenyl)pyridine (1e) (46 mg, 
0.25 mmol) and B2cat2 (62b) (59 mg, 0.25 mmol) in 1,4-dioxane (1.0 mL). After 20 h, 
purification by flash column chromatography on silica gel (n-hexane/Et3N/EtOAc: 8/2/90). 
yielded 70eb (60 mg, 79%) as a grey color solid. 
 
M.p.: 160-162 °C 
 
1H NMR (400 MHz, CDCl3): δ = 8.10 (ddd, J = 5.6, 1.5, 0.9 Hz, 1H), 7.98 (ddd, J = 8.1, 7.5, 
1.5 Hz, 1H), 7.74 (dt, J = 8.1, 1.0 Hz, 1H), 7.66 (dd, J = 8.5, 0.5 Hz, 1H), 7.25 (d, J = 2.2 Hz, 
1H), 7.20 (ddd, J = 7.5, 5.6, 1.1 Hz, 1H), 6.94–6.89 (m, 3H), 6.83–6.78 (m, 2H), 3.86 (s, 3H). 
 
13C NMR (101 MHz, CDCl3): δ = 163.4 (Cq), 155.7 (Cq), 152.3 (Cq), 143.5 (CH), 142.2 (CH), 
129.9 (Cq), 123.4 (CH), 122.1 (CH), 119.5 (CH), 117.2 (CH), 116.7 (CH), 115.3 (CH), 110.3 
(CH), 55.6 (CH3).  
 
11B NMR (128 MHz, CDCl3): δ = 13.3 
 
IR (neat): ṽ = 2938, 1611, 1479, 1469, 1348, 1220, 1014, 865, 770 cm−1. 
 
MS (EI) m/z (relative intensity) 303 (100) [M+], 302 (29), 288 (25), 260 (25), 259 (24), 230 
(9).  
HR-MS (EI) m/z calcd for C18H14BNO3 [M+] 303.1067, found 303.1079. 
 






5.7 Ruthenium-catalyzed C(sp3)–H bond borylations 






The general procedure E was followed using substrate 73a (81 mg, 0.50 mmol), B2Pin2 (62a) 
(190 mg, 0.75 mmol), in 1,4-dioxane (2 mL). After 16 h, purification by flash column 
chromatography (EtOAc/NEt3: 98/2) yielded 74aa (35 mg, 24%) as a brown solid. 
M.p: 130-132 °C. 
1H NMR (400 MHz, CDCl3): δ = 7.76 (ddd, J = 6.0, 1.6, 0.7 Hz, 1H), 7.21 (ddd, J = 7.0, 1.6, 
0.9 Hz, 1H), 6.43 (dd, J = 7.0, 6.0 Hz, 1H), 3.68 (td, J = 9.1, 1.7 Hz, 1H), 3.24–3.14 (m, 1H), 
2.75 (dd, J = 12.2, 6.0 Hz, 1H), 2.21 (s, 3H), 2.06 (dtt, J = 12.0, 6.8, 1.4 Hz, 1H), 1.92 (tddd, 
J = 12.1, 10.2, 8.8, 6.3 Hz, 1H), 1.80 (dtd, J = 12.4, 6.2, 1.2 Hz, 1H), 1.50 (qd, J = 12.2, 
6.6 Hz, 1H), 1.16 (s, 12H). 
13C NMR (101 MHz, CDCl3): δ = 159.6 (Cq), 142.2 (CH), 137.1 (CH), 120.1 (Cq), 112.2 (CH), 
79.2 (Cq), 59.0 (CH), 49.9 (CH2), 29.9 (CH2), 27.4 (CH2), 26.3 (CH3), 18.9 (CH3). 
 
11B NMR (128 MHz, CDCl3): δ = 9.71 (s). 
 
IR (neat): ṽ = 2962, 1619, 1498, 1478, 1240, 1079, 971, 780, 753 cm−1. 
 
HR-MS (ESI): m/z calcd for C16H26BN2O2+ [M+H+] 289.2082, found 289.2085 
 






Radical scavenger experiments 
The general procedure E was followed using substrate 73a (81 mg, 0.50 mmol), B2Pin2 (62a) 
(190 mg, 0.75 mmol), and radical scavenger in 1,4-dioxane (2 mL). After 16 h, an aliquot 





The general procedure E was followed using substrate 73a (81 mg, 0.50 mmol), B2Pin2 (62a) 
(190 mg, 0.75 mmol), and Hg (200 mg, 1.00 mmol) in 1,4-dioxane (2.0 mL). After 16 h, an 
aliquot was removed and analyzed by GC and GC-MS with n-dodecane as internal standard. 





B2pin2 (62a) (13 mg, 0.05 mmol) and [Ru(O2CMes)2(p-cymene)] (16) (14.0 mg, 0.025 mmol) 
were placed in a pre-dried pressure tube equipped with a rubber septum. The tube was 
evacuated and flushed with N2 three times and 1,4-dioxane (0.3 mL) was added and the 
reaction mixture was stirred at 110 °C for 4 h and then 73a (4.0 mg, 0.025 mmol) was added 








The rubber septum was replaced by the pressure tube screw cap, stirring was continued at 
110 °C for 12 h and analyzed by GC and GC-MS with n-dodecane as internal standard. The 




Reaction with cycloruthentaed complex 82 
The general procedure D was followed using 2-(4-methoxyphenyl)pyridine (1e) (46 mg, 
0.25 mmol), B2cat2 (62b) (59 mg, 0.25 mmol) and cycloruthenated compled (82) (7 mg, 
5.0 mol %) in 1,4-dioxane (1.0 mL). After 20 h, purification by column chromatography on 
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